**George D. Bittner, CV**

March 2023

A. *PERSONAL DATA*

Full Name: George Davis Bittner

Place and Date of Birth: August 17, 1941; New York, NY

Marital Status: Married (Dr. Cathy Yang, MD, PhD)

Children: Jack, Lucie

Current Home Address: 2812 Pearce Road, Austin, Texas 78730

 (512) 346‑4392

Current Office Address: Patterson Laboratories, Room 321

 Department of Neuroscience

 University of Texas

 Austin, TX 78712-1064

 (512) 923-3735 (cell). preferred # to call

 (512) 471-6971 (Lab)

 email: bittner@austin.utexas.edu

 web site <https://sites.cns.utexas.edu/bittnerlab>

B. *EDUCATION*

9/56- 6/59 Robert E Lee High School, Jacksonville, FL ranked 1/838 Valedictorian

9/59 ‑ 6/62 Duke University, Durham, NC; A.B., Chemistry, 9/62

9/62 ‑ 12/66 Stanford Medical School, Palo Alto, CA; 5 year MD/PhD program. Withdrew in good standing (sixth in class) 12/66 via leave of absence in December of fifth year to devote full time to research,

6/64 ‑ 8/67 Stanford University; Ph.D., Neurological Sciences, 1967; Supervising Professor: Dr. Donald Kennedy, Chairman, Biological Sciences, FDA Commissioner, President of Stanford University, Chief Editor of *Science and Scientific Americsan*

11/67 ‑ 6/69 NIH Postdoctoral fellowship with Dr. Jose Segundo, Department of Anatomy/Cell Biology, UCLA, Los Angeles, CA

C. *PROFESSIONAL EXPERIENCE*

CEO CertiChem 5/00 – present, CEO PlastiPure 5/00 – 6/08, CSO PlastiPure 7/08 – present

Professor, Department of Neuroscience, 9/2013 - present

Professor, Neurobiology Section, School of Biology, 9/98 – 8/2013

Professor, Dept. of Zoology, University of Texas, Austin, TX, 9/82 – 8/98

Adjunct Professor, College of Pharmacy, University of Texas, Austin, TX, 9/87 – 5/05

Associate Professor, Department of Zoology, University of Texas, 9/74 ‑ 8/82

Assistant Professor, Department of Zoology, University of Texas, 9/69 ‑ 8/74

Adjunct Professor, Dept. of Physiology and Biophysics, University of Texas Medical Branch,

 Galveston, TX, 3/96 - present

Visiting Associate Professor, Department of Physiology, University of Texas Medical School, San Antonio, TX, 9/77 ‑ 8/78

Visiting Associate Professor, Department of Anatomy, Case‑Western Reserve University Medical School, Cleveland, OH, 8/75 ‑ 1/76

NIH Postdoctoral Fellow, Dr. Jose Segundo, Department of Anatomy, UCLA, 11/67 ‑ 6/69

NIH Predoctoral Fellow, Dr. Donald Kennedy, Biological Sciences, Stanford University, 1965 ‑ 67

Research Assistant, Dr. Keith Killam, Department of Pharmacology, Stanford University, 1962 ‑ 63

D. *UNIVERSITY ADMINISTRATIVE RESPONSIBILITIES (since 1985)*

Biology Graduate Advisor, 1982 - 1990

Program Director, Neurobiology Training Grant, 1985 - 1991

Program Director, Electron Microscope Applications to NIH, NSF, 1985 - 1986

Organizing Director, Institute for Neuroscience, 1985 - 1986

Member, Executive Committee, Institute for Neuroscience, 1986 - 1994

Member, Executive Committee, Institute for Biotechnology, 1988 - 1995

Natural Science Promotion Committee (2002-2004; Chair, 2003-2004)

Natural Sciences Courses and Curricula committee (2003-2005)

CNS Scholarship Committee (2002-present)

University of Texas Libraries Committee (8/2014-2019); Chair 2017-2018

Student Conduct Hearing Officer (9/2016-2020)

Reviewer of 2-5 URF proposals yearly (2018 present)

CNS FRA committee 2019-present

E. *PROFESSIONAL SOCIETIES* Past and present\*

Society for Neuroscience\* Neurotrauma Society

A.A.A.S. (Elected Fellow)\* Society for Cell Biology

Society for Neurochemistry Society for Developmental Neurobiology

American Chemical Society\* Endocrine Society\*

F. *PROFESSIONAL AND PUBLIC SERVICE (Since 1985)*

Member, NINCDS Review Committee for Program Project Grants, 1986 - 1987

Member, Advisory Committee for Basic Neuroscience Research, Air Force Office of Sponsored Research, 1987 - 1988

Vice President, Central Texas Biotechnology Consortium, 1986 - 1989

Member, Neuroscience Review Committee for Veteran Administration Grants, 1990

Treasurer, Society for Neuroscience (Austin Chapter), 1985 - 1996

Member, Biotechnology Committee, Austin Chamber of Commerce, 1987 - 1994

Member, NSF and Howard Hughes Panels for Predoctoral Fellowships in Neurobiology, 1993 - 1995

Chair, Neuroscience Panel for Howard Hughes and NSF Predoctoral Fellowships, 1996Editorial Review Board, Neural Regeneration Research since June 2015

Review 8-15 Manuscripts/year total for *Journal of Neurophysiology*, *Journal of Comparative Physiology*, *Science*, *Journal of Neurobiology*, *Brain Research*, *Journal of Neuroscience*, *Toxicology in Vitro*, *Toxicological Sciences*, *Environmental Health Perspectives, Environmental Health, Neural Regeneration Research, PLos one, J. Neuroinflammation, Progress in Neurobiology*

Ad Hoc Reviewer, NIH, NSF Neurobiology Grant Applications in Synaptic Plasticity, Nerve Regeneration, or Glial Function, 1985 – present

Member NIH BNVT panel study section, panel to review/score R-01, R-21, U-01, U-03 etc grant applications. 8/2014.

Member Editorial Board. Neural Regeneration Research. 2019-present

Guest Editor, Frontiers in Cellular Neuroscience, Edition on *Restoring Function After Traumatic Peripheral Nerve Injury.* 2021-2022

G. *INVITED SEMINARS/PRESENTATIONS (2005-2020)*

 Robert Wood Johnson Medical School, Piscataway, NJ (April, 2005)

 NIEHS Campus, Research Triangle Park, NC (April, 2005; August, 2006)

 Lone Star Paralysis Foundation, Austin, May 2006

 Brain, Spine Center, Brackenridge Hospital, Nov 2006

 Department of Biology, North Carolina State University, Raleigh NC (March 2007)

 Breast Cancer Foundation/Fund San Francisco, Ca. Detection of estrogenic activity in plastics

 (Jan, 2008)

 Lone Star Paralysis Foundation, Axonal repair using polyethylene glycol (April, 2008)

 NIH/NIEHS Campus Raleigh, NC detection of estrogenic activity. (March, 2009).

 A Robotic MCF-7 Cell Proliferation Assay to Detect Estrogen Receptor Agonists and Antagonists 2010. C.Z. Yang, N. Bodon and G.D. Bittner, Society of Toxicology., March 2010, Salt Lake City

 Almost all plastics release chemicals having estrogenic activity: a health problem that can be solved. NIEHS research campus, NC. 1.14.11.

Rapid Repair of Severed Nerve Axons. Harvard Medical School, Dept of Orthopedic Surgery . Dec. 2011

Rapid Repair of Severed Nerve Axons. Concordia University, Dept of Biology, Feb, 2012

Rapid Repair of Severed Nerve Axons. University of Texas, Psychology Dept, Feb 2012

Rapid Repair of Severed Nerve Axons. Wayne State Medical School, Anatomy/Cell Biology, Feb 2012

Rapid Repair of Severed Nerve Axons. U. Miami Medical School, Dept. of Orthopedic Surgery, March 2012

Rapid Repair of Severed Nerve Axons. Department of Biology, North Carolina State University, April, 2013

Rapid Repair of Severed Nerve Axons. Department of Biomedical Engineering, NC State University, April, 2013

Rapid Repair of Severed Nerve Axons. Department of Neurosurgery, Duke University Medical School, April, 2013

Rapid Repair of Severed Nerve Axons. Department of Orthopedics and Plastic Surgery and Neuroscience Program, Wake Forrest Medical School, April, 2013.

Plastics and Chemicals in the Environment. Sierra Club. Austin, TX September 2013.

Bioengineered repair of severed limb nerves. UT Quest. March 2014.

Rapid restoration of behaviors lost after completely severing peripheral limb nerves:
 It’s not just for Luke Skywalker and (Mr.) Crabs anymore U. Virginia, Biology Dept. Oct 2014.

Rapid restoration of behaviors lost after completely severing peripheral limb nerves:
 It’s not just for Luke Skywalker. University of Indiana Medical School. March, 2015.

Biotech Advances in Hormone Free products. UT Quest. March, 2015.

A battery of in vitro assays to detect estrogenic activity. ICCVAM Conference, NIH, May, 2016

|  |  |  |  |
| --- | --- | --- | --- |
| 2019-10  |  | Metis Foundation, San Antonio,Tx | Axonal Repair by PEG-fusion  |
| 2019-10  |  | UT Lifelong learning | Rapid repair of severed axons... Its not just for Mr. Crabs and Luke Skywalker  |
| 2019-12  |  | Johns Hopkins Medical School | Rapid Repair of severed axons by PEG-fusion  |
| 2020-6 Univ of Illinois Med Sch  | Rapid repair of severed axons by PEG-fusion |
| 2021 -3 Univ. Wyoming | Rapid Repair of Nerve Axons by PEG-fusion |

2022-4 Am Assoc Neuro Surgeons Rapid Repair of Nerve Axons by PEG-fusion

Invited Speaker

H. *AWARDS AND HONORARY SOCIETIES*

First Prize, Florida State Science Fairs, 1958, 1959

Valedictorian, Robert E. Lee High School (Class size ~800)

Phi Eta Sigma, Freshman Honorary, Duke University, 1959 - 1960

Phi Beta Kappa, Phi Eta Sigma, Duke University, 1962

A.B., Magna Cum Laude, Duke University, 1962

NIH, NSF predoctoral fellowships, Stanford University, 1965 - 1966

NIH postdoctoral fellowship, UCLA, 1967 - 1969

Fellow, Neurosciences Study Program, Boulder, CO, Summer 1969

NIH Career Development Award, 1975-1980

Elected Fellow, American Association for the Advancement of Science, Spring, 1994

ICCVAM/NICEATM Advisory panel 2018-2021

Guest Editor, Frontiers in Cellular Neuroscience, Edition on *Restoring Function After Traumatic Peripheral Nerve Injury.* 2021-2023 (publication date)

Associate Editor, Frontiers in Cellular Neuroscience, 9/22-

I. *UNIVERSITY AND DEPARTMENTAL COMMITTEES (Since 1985)*

Zoology, Long Range Planning Committee, 1984 - 1986

Zoology, Chairman Recruitment Committee, 1985 - 1986

Faculty Advisor Graduate Fellows Program, 1985 - 1986

Selection Committee, Churchill Scholar Program, 1985 - 1987

Plan II Advisory Committee, 1986 - 1990

Zoology Computer Committee, 1987 - 1990

Zoology, Admissions Committee, 1989 - 1990

Dean's Committee to Revise Plan II Curriculum, 1986 - 1992

Zoology, Cell Biology Search Committee (Chair), 1991 - 1992

Zoology, Departmental Visiting Committee, 1988 - 1993

Dean of Natural Science, Industrial Associates Committee, 1988 - 1994

Zoology Electron Microscope Committee, 1985 - 1998

Zoology, Industrial Liaison, 1988 - 1996

Zoology, Fellowship Committee, 1990 – 1998

Natural Sciences Courses and Curricula committee (2003-2005)

Biology Fellowship Committee (1999-2018)

CNS Scholarship Committee (2002-present)

University of Texas Libraries Committee (8/2014-8/2020); Chair 9/2018- 8/2019

Student Conduct Hearing Officer (9/2016-2020Reviewer URF proposals 2018-present

Letters of recommendation for 8-15 students/yr to graduate/medical schools 2000-present

Reviewer for Faculty Research Assignment Competition. 2020- present

J. *COURSES TAUGHT*

 **1. Undergraduate Courses**

 Mammalian Physiology (Zoology 465M)

 Vertebrate Physiology (Zoology 365L, Biology 365R, NEU 365R)

 Vertebrate Physiology Laboratory (Zoology 165P)

 Human Physiology (Zoology 316K)

 Structure and Function of the Mammalian Central Nervous System (Zoology 371L)

 Physiology of Organismic Adaptations (Zoology 363L, 363M)

 Adaptive Physiology Laboratory (Zoology 263P)

 Current Limits of Scientific Knowledge (TC 659: Plan II Honors Section)

 The Neuronal Basis of Brain and Behavior (Zoology 371L, Biology 371M)

 Comparative Physiology (Biology 361T)

 Nerve Regeneration in Invertebrates and Vertebrates. Writing component course (NEU 337 or NEU365N)

 **2. Graduate Courses**

 Advanced Cell Biology (Zoology 388M)

 Principals of Neuroscience (Zoology 688QA, B;NEU 382T; NEU 383T, BIO 437; NEU 482T)

 Developmental Neurobiology (Zoology 390K; Biology 390K)

 Adaptive Physiology of Marine Organisms (MNS 382.12 at The University of Texas Marine Station at Port Aransas)

 Cellular Neurobiology (Anatomy 449 at Case Western Reserve University)

 Basic Properties of Nerve Cells: Axonal Conduction and Synaptic Transmission (Zoology 385L.13a; Biology 381K))

 Basic Properties of Nerve Cells: Trophic Interactions and Regeneration (Zoology 385L.13b; Biology 381K)

 Current Concepts in Cellular/Molecular Neuroscience (Zoology 385L.15; Biology 381K))

 Neurophysiology of Nerve and Muscle, (UTSA Department of Physiology)

 Environmental Physiology (Marine Science 354 at The University of Texas Marine Science Institute, Port Aransas, TX)

 Basic Properties of Nerve Cells: Metabolic, Glial-Neuronal, and Regeneration. (BIO. 381K.10/NEU 385L.1).

 Nerve Regeneration in Invertebrates and Vertebrates (NEU 381N.1, NEU 381N)

K. *INDIVIDUAL INSTRUCTION*

*Supervision of Undergraduate Students*

I perform a significant amount of individual research instruction with undergraduates who often register for BIO research courses, Biology Honors, or Plan II thesis courses. Whether they officially register or not, each student makes a commitment to work 10-20 hours per week for at least 18 months and to take a series of courses in cell, molecular, and/or neurobiology to give them an appropriate conceptual and factual basis for their research. By the time they graduate, most such students are a co-author in at least one peer-reviewed publication and participate in weekly lab journal club/data presentation meeting. Those undergraduate students in my lab doing such meeting such criteria in the past ten years were as follows:

Student In Lab

 Cameron Ghergherehchi 2011-2015

 Christopher Driscoll 2012-2014

 Robert Hastings 2012-2014

 \*Chris McGill ` 2012-2018

 Colton Riley 2012-2014

 Ti Ha 2013-2015

 Nicholas Munoz 2013-2015

 \*Andrew Poon 2014-2018

 Monika Pyarali 2013-2016

 Michael Bounajem 2014-2016

 Alex Mazal 2014-2016

 Aakarshita Bansal 2015-2016

 Patrick Dunne 2015-2017

 Maui Guitterrez 2014-2017

 Nicole Wong 2015-2017

 Amir Ali 2015-2018

 Zach Burgess 2016-2017

 Adrian Gorszawski 2016-2017

 Sarah Nguyen 2016-2019

 Matthew Hooper 2016-2018

 Karthik Jagannath 2016-2018

 Edward Kang 2017-2019

 Milki Negeri 2018-2019

 Meghana Gogineni 2018-2019

 Kenneth Pham 2018-2020

 Ted Zhao 2018-2020

 Bryan Nyakiti 2018-2021

 Shruti Kumar 2018-2019

 Sara Vargas 2018-2020

 Monzer Alatrach 2018-2021

 Grace Massamillo 2018-2019

 \* Sruja Arya 2019-present

 \*Mario Carrera 2019- present

 Razan Hussein 2019-2020

 ` Vanessa Nuval 2019-2020

 Marshal Mencel 2019-5/2021

 Anirudh Sudarshan 2020-2021

 Rhea Sachdeva 2020-2022

 \* Menizhe Mohsin 2021-present

 Anish Pandya 2021-2022

 \* Yessennia Montoya 2021-present

 \* Alexa Olivarez 2021-present

 \* Karthik Venkudusamy 2021-present

 \* Jesus Jimenez 2022-present

 \*Stone Nwamadi, 2022-present

 \*Anaya Sampathkumar 2022-present

 \* currently active

Many undergraduates in my laboratory (Aesher, Baskind, Cummings, Farnam, Garcia, Hsu, Lichstein, Loftin, Lusco, Nguyen, Storm, Thomas, Truchard, and Weiner) have been awarded NIH or Howard Hughes Fellowships for the summer, four (Bobb, Eddleman, Sterkenburg, and Todora) have been awarded fellowships at Woods Hole, and five (Bobb, Brown, Loftin, Sunio, Wade, Vargas, Montoya) have been awarded ATP or other Minority Fellowships. Almost all students who had worked in my laboratory have been admitted to excellent medical or graduate schools (Cummings - Cell and Molecular Biology, UCSF; Cobb - Biology, UC Berkeley; Storm - Cell and Molecular Biology, Stanford; Truchard - Biology, UC Berkeley; Todora - Neurobiology, Harvard; Weiner - Cell and Molecular Biology, UCSF; Hristov – Johns Hopkins Medical School; Marzullo – Neuroscience, Univ. of Michigan: Truong –University of Texas Medical School at Houston; Rossano, Driscoll, Burgess: UT Medical School San Antonio; Covington/Figard – Rice University; Boydston, Ha-Southwestern Medical School, Hastings: Neuroscience, Texas A&M, Riley: Georgetown Medical School. Mazal-Southwestern Medical School: Pyarali-Baylor Medical School;McGill, Yale; Ali, Jagannath: UT Me4dical School, Houstin). Many have won Research Grants or other honors at UT (Cummins, Hsu, Truchard, Todora, Weiner, Rossano, Robinson, Jang, Covington, Boydston, Ha, Pyarali, Mazal, Kang, Zhou, Poon, McGill, Mencel, Vargas)

Publications since 1996 of former undergraduates (asterisked\*):

T.D. Raabe, T. Nguyen,\* and G.D. Bittner. 1996. Calcium activated proteolysis of neurofilament proteins in goldfish Mauthner axons. J. Neurobiol. 6:253-261.

T.D. Raabe, T. Nguyen,\* C. Archer,\* G.D. Bittner. 1996. Mechanisms for the maintenance and eventual degradation of neurofilament proteins in the distal segments of sered goldfish Mauthner axons. J. Neurosci. 16:1605-1613.

O. Weiner,\* A.M. Zorn, P.A. Krieg, and G.D. Bittner. 1996. Medium weight neurofilament mRNA in goldfish Mauthner axoplasm. Neurosci. Lett. 213:83-86.

Sunio\* and G.D. Bittner. 1997. Cyclosporin retards the Wallerian degeneration of peripheral mammalian axons. Exp. Neurol. 146:46-56.

C.S. Eddleman,\* M.L. Ballinger, M.E. Smyers, C.M. Godell,\*H.M. Fishman, and G.D. Bittner. 1997. Repair of plasmalemmal lesions by vesicles. PNAS 94:4745-4750.

C.M. Godell,\* M.L. Ballinger, C.S. Eddleman,\* M.E. Smyers, H.M. Fishman, and G.D. Bittner. 1997. Calpain promotes the sealing of severed giant axons. PNAS 94:4751-4756.

M.L. Ballinger, A.R. Blanchette, T.L. Krause,\* M.E. Smyers, H.M. Fishman, and G.D. Bittner. 1997. Delaminating myelin membranes help seal the cut ends of severed earthworm giant axons. J. Neurobiol. 33:945-960.

C.S. Eddleman,\* M.L. Ballinger, M.E. Smyers, H.M. Fishman, and G.D. Bittner. 1998. Endocytotic Formations of vesicles and other membranous structures induced by Ca2+ and axoplasmic injury. J. Neurosci. 18:4029-4041.

C.S. Eddleman,\* M.E. Smyers, A. Lore,\* H.M. Fishman, and G.D. Bittner. 1998. Anomalies associated with dye exclusion as a measure of axolemmal repair. Neurosci. Lett. 256:13-126.

A.B. Lore,\* J.A. Hubbell, D.S. Bobb Jr., M.L. Ballinger, K.L. Loftin,\* J.W. Smith,\* M.E. Smyers, H.D. Garcia,\* and G.D. Bittner. 1999. Rapid induction of functional and morphological continuity between severed ends of mammalian or earthworm myelinated axons. J. Neurosci. 19:2442-2454.

J.W. Lichstein,\* M.L. Ballinger, A.R. Blanchette, H.M. Fishman, and G.D. Bittner. 1999. Structural changes at the cut ends of earthworm giant axons in the interval between dye barrier formation and Neuritic outgrowth. J. Comp. Neurol. 416:143-157.

C.S. Eddleman,\* G.D. Bittner and H.M. Fishman. 2000. Barrier permeability at cut axonal ends progressively decreased until an axonal seal is formed. Biophys. J., 79:1883-1890.

E. Detrait, C.S. Eddleman, S. Yoo, M. Fukuda, G.D. Bittner and H.M. Fishman. 2000. Axolemmal repair requires proteins that mediate synaptic vesicle fusion. 2000 J. Neurobiol. 44:382-391.

E. Detrait, S. Yoo, T. Nguyen,\* C.S. Eddleman, M. Fukuda, G.D. Bittner, and H.M. Fishman. 2000. Repair of severed neurites of PC 12 cells requires divalent cations and a concerved region of synaptotagmin. J. Neuroscience Research. 62:566-573

T. C. Marzullo\*, J.S. Britt\*, R. Stavisky and G.D. Bittner. 2002. Cooling enhances in vitro survival and fusion-repair of severed axons taken from the peripheral and central nervous system of rats. Neuroscience Letters. 327:9–12.

C.S. Eddleman\*, G.D. Bittner, and H.M. Fishman. 2003. SEM comparison of severed ends of giant axons isolated from squid (*Loligo pealei*) and crayfish (*Procambarus clarkii*). Biol Bull. 203: 219 – 220.

S. Yoo, M. P. Nguyen\*, M. Fukuda, G. D. Bittner, and H. M. Fishman. 2003. Plasmalemmal sealing of transected mammalian neurites is a gradual process mediated by Ca-regulated proteins. J. Neurosci. Res. 74:541-551.

R. C. Stavisky, J. M. Britt,\* T. Pham\*, T. C. Marzullo\* and G. D. Bittner. 2003. Wallerian Degeneration of mammalian PNS and CNS axons is accelerated by incubation with protein synthesis inhibitors. Neuroscience Res. 47: 445 – 449.

R.C. Stavisky, J.M. Britt\*, A. Zuzek\*, E. Truong\* and G.D. Bittner. 2005. Melatonin enhances the in vitro and in vivo repair of severed rat sciatic axons. Neurosci. Letters, 98-101.

M. G. Nguyen\*,G.D. Bittner, and H.M. Fishman, H.M. 2007. Critical interval of sodium calcium transient after neurite transaction determines B104 cell survival. J. Neurosci. Res., 805-816.

J. M. Britt\*, J.R. Kane, C.S. Spaeth, A. Zuzek\*, G.L.Robinson\*, M.Y. Gbanaglo, C.J. Estler\*, E.A. Boydston\*, T. Schallert, T and G.D. Bittner. (2010). Polyethylene glycol rapidly restores axonal integrity and improves the rate of motor behavior recovery after sciatic nerve crush injury. J Neurophysiol., 104: 695-703

C. S. Spaeth, E.A. Boydston\*, L.A. Figard\*, A. Zuzek\* and G.D. Bittner (2010). A model for sealing plasmalemmal damage in neurons and other eukaryotic cells. J. Neurosci. 30: 15790-15800.

Spaeth CS, Fan, GD\*, Spaeth EB, Robison T\*, Wilcott RW\*, Bittner GD (2012) Neurite transection produces cytosolic oxidation which enhances plasmalemmal repair. *J Neurosci Res*.90:945-954

Spaeth CS, Robison TR, Fan, JD, Bittner GD (2012) Cellular mechanisms of plasmalemmal sealing and axonal repair by polyethylene glycol and methylene blue. *J. Neurosci. Res.* 90:955-966.

Bittner, GD C.P. Keating, J. R. Kane, J.M. Britt\*, C. S. Spaeth, J. D. Fan\*, A. Zuzek,\* R. W. Wilcott\*, W. P. Thayer, J.M. Winograd, F. Gonzalez-Lima and T. Schallert. (2012)Rapid, effective and long-lasting behavioral recovery produced by microsutures, methylene blue

 and polyethylene glycol after complete cut of rat sciatic nerves*. J Neurosci Res*. 90:967-980.

Spaeth CS, Boydston EA\*, Wilcott RW\*, Fan JD\*, Robison T\*, Bittner,GD (2012) Pathways for plasmalemmal repair mediated by PKA, Epac and cytosolic oxidation in rat B104 cells *in vitro* and rat sciatic axons *ex vivo*. *Devel Neurol.*, 72: 1399-1414.

 Zuzek A\*, Fan JD\*, Spaeth CS, Bittner GD. 2013. Sealing of transected neurites of rat B104 cells requires a diacylglycerol PKC-dependent pathway and a PKA-dependent pathway. Cell Molec Neurosci. 33: 31-46.

Rodriguez-Feo CL, K.W. Sexton,R. B. Boyer, A. C. Pollins,N. L. Cardwell, L. B. Nanney,R. B. Shack, M. A. Mikesh,C. H. McGill\*, C. W. Driscoll\*, G. D. Bittner, W. P. Thayer. 2013. Blocking the P2X7 Receptor Improves Outcomes After Axonal Fusion. J. Surgical Research. . 184(1):705-13. doi: 10.1016/j.jss.2013.04.082.

D.C. Riley\*, G.D. Bittner, M.A. Mikesh, N.L. Cardwell, A.C. Pollins, C.L. Ghergherehchi\*, S.R. Bhupanapadu Sunkesula, T.N. Ha,\* B.T.D. Hall\*, A.D. Poon\*, M. Pyarali\*, R.B. Boyer, A.T. Mazal\*, N. Munoz\*, R.C. Trevino, T.Schallert, W.P. Thayer. (2014) PEG-fused allografts produce rapid behavioral recovery after ablating sciatic nerve segments. J. Neurosci. Res. Apr;93(4):572-83. doi: 10.1002/jnr.23514. PubMed PMID: 25425242; PubMed Central PMCID: PMCPMC4329031.

G.D. Bittner, D.R. Sengelaub, R.C. Trevino, J.D. Peduzzi, M. Mikesh, C.L. Ghergherehchi\*, T.Schallert, W.P. Thayer. 2015. The curious ability of PEG-fusion technologies to restore lost behaviors after nerve severance. J Neurosci Res. J Neurosci Res. 94: 207-230. online 3 Nov.2015. doi. 1002/jnr 23685

C. L. Ghergherehchi\*, G. D. Bittner, R. L. Hastings\*, M. Mikesh, D. C. Riley\*, R. C. Trevino, T. Schallert, W. P. Thayer, S. Raju Bhupanapadu Sunkesula,, T-A. N. Ha\*\, N. Muno\*, M. Pyarali\*, A. Bansal\*, A. D. Poon\*, A. T. Mazal\*, T. A. Smith, N. S. Wong\*, P. J. Dunne\*. 2015. Effects of extracellular calcium and surgical techniques on restoration of axonal continuity by PEG-fusion following complete cut- or crush-severance of rat sciatic nerves. J Neurosci Res. 94:231-235. Doi. 10.1002/jnr23704 . Epub Jan 5, 2016

G.D. Bittner, M. Mikesh, C. L. Ghergherehchi\*. 2016. PEG-fusion retards Wallerian degeneration and rapidly restores behaviors lost after nerve severance. Neural Regen. Res. 11:217-219. Doi 10.4103/1673-5374.177716

C.H. McGill\*, S. R. Bhupanapadu Sunkesula, A.D. Poon\*,M. Mikesh, G. D. Bittner. 2016. Sealing Frequency of B104 Cells Declines Exponentially with Decreasing Transection Distance from the Axon Hillock. Exp. Neurol. 279:149-158. doi:10.1016/j.expneurol.2016.02.001

G.D. Bittner, D.R. Sengelaub, R.C. Trevino, C.L. Ghergherehchi\*, M. Mikesh. 2016.Robinson and Madison have published no data on whether polyethylene glycol fusion repair prevents reinnervation accuracy in rat peripheral nerve. J Neurosci Res. In Press.

George D. Bittner, Christopher S. Spaeth, Andrew D. Poon\*, Zachary S. Burgess\*, Christopher H. McGill\*. 2016. Repair of traumatic plasmalemmal damage to neurons and other eukaryotic cells. Neu. Regen. Res. Exp. Neurol. 279:149-158. doi:10.1016/j.expneurol.2016.02.001

G.D. Bittner, M. Mikesh, C. L. Ghergherehchi. 2016. PEG-fusion retards Wallerian degeneration and rapidly restores behaviors lost after nerve severance. Neural Regen. Res. 11:217-219. Doi 10.4103/1673-5374.177716

GD Bittner, DL Sengelaub, CL Ghergherehchi\*. 2018. Conundrums and confusions regarding how PEG-fusion produces excellent behavioral recovery after peripheral nerve injuries. Neural Regeneration Research. 13: 53-57..

Andrew D. Poon\*, Sarah H. McGill\*, Solomon Raju Bhupanapadu Sunkesula, Zachary S. Burgess\*, Patrick J. Dunne\*, Edward E. Kang\* and George D Bittner. 2018.CaMKII and DMSO affect the sealing frequencies of transected hippocampal neurons. J. Neurosci. Res. 96:1208-1222.

Mikesh M, Ghergherehchi CL\*, Hastings RL\*, Ali A, Rahesh S\*, Jagannath K\*, Sengelaub DR, Trevino RC, Jackson DM, Bittner GD. 2019. Polyethylene glycol solutions rapidly restore and maintain axonal continuity, neuromuscular structures and behaviors lost after sciatic nerve transections in female rats. J. Neurosci. Res. 96: 1223-1242.

Mikesh M, Ghergherehchi CL\*, Rahesh \*, Jagannath K\*, Ali A\*, Sengelaub DR, Trevino RC, Jackson DM, Tucker HO, Bittner GD. 2019. Polyethylene glycol treated allografts not tissue matched nor immunosuppressed rapidly repair sciatic nerve gaps, maintain neuromuscular functions, and restore voluntary behaviors in female rats. J. Neurosci. Res. 96:1243- 1264.

Ghergherehchi CL\*, Mikesh M, Sengelaub DR, Jackson DM, Smith T, Shores JT, Bittner GD. (2019) Polyethylene glycol (PEG) and other bioactive solutions with neurorrhaphy for rapid and dramatic repair of peripheral nerve lesions by PEG-fusion. J Neurosci Methods. 314:1-12.

Vargas SA\* and Bittner GD. 2019. Natural mechanisms and artificial PEG-induced mechanism that repair traumatic damage to the plasmalemma in eukaryotes. Current Topics in Membranes: Plasma Membrane Repair. 84: 129-167.

L. *GRADUATE STUDENT SUPERVISION. Last known position*

1. *M.A. Degrees:*

*Completed*

R.T. Kopanda. 1973. Trophic interactions in the crayfish, *Procambarus clarkii*. Deputy Director of ADAMHA.

L. Boone. 1973. Trophic dependencies in a crustacean muscle. Currently a practicing M.D.

M. Nitzberg. 1973. Ultrastructural changes in transplanted segments of crustacean peripheral nerves. Currently a science advisor to a computer firm.

Obichere Nwabuko. 1976. The roles of calcium in vertebrate muscle contraction. Current position unknown.

M.S. Bouton. 1980. Mechanisms of axonal regeneration in crayfish motor axons. Currently a practicing M.D..

Todd Miller. 1990. Role of synapsin in neurotransmitter release. Current position unknown.

Melva Avalos. 1990. The effect of pentobarbital on pre- and postsynaptic channels at crayfish neuromuscular junctions. Current Position Unknown.

Guillermo Espinoza. 1992. Morphological correlates of longterm potentiation at hippocampal synapses. (Co-directed with Dr. Abraham Amsel of Psychology).

Tonya Thompson. 1992. Neurochemistry of monoamine oxidase enzymes and neurotoxins. (Co-directed with Dr. Creed Abell, Department of Pharmacology). Practicing MD..

Qi-Quan Huang. 1993. Molecular biology of muscle development. (Co-directed with Kuan Wang of Biochemistry). Research associate in Canada.

Tia Sea. 1993. Effect of temperature on survival of severed distal stumps of mammalian axons. Currently a practicing nurse.

Cecilia Smith. 1994. Neurite outgrowth in organ culture. Address Unknown

Chris Godell. 1995. Calpain-induced sealing of severed nerve axons. Practicing MD..

Arisa Sunio. 1995. The immunosuppressant cyclosporin A retads the degeneration of distal segments of mammalian axons. Research Associate, Southwestern Medical School, Dallas, TX.

Adam Blanchette. 1998. Changes in configuration and location of membranous structures that seal the cut ends of earthworm giant axons. Currently a Research Associate at UT Medical School, San Antonio, TX

*2. Ph.D. Degrees:*

*Completed*

Milton P. Charlton. 1975. Parameters of transmitter release in squid synapses. Professor Emeritus of Physiology at Toronto University.

Lawrence W. Powers. 1975. Physiological and ecological correlates of burrowing behavior in fiddler crabs. Professor and Chairman, Department of Medical Technology, University of South Alabama, Mobile, AL.

Mark E. Meyer. 1977. Histological and biochemical studies of trophic dependencies in crayfish giant axons. Professor of Biology at University of Washington (Seattle).

Stewart C. Birse. 1979. Mechanism and specificity of giant axon regeneration in the earthworm central nervous system. Practicing M.D.

Claire E. Hulsebosch. 1979. Regeneration of axons and cell bodies in the central nervous system of annelids: a test of the neuron addition hypothesis. Professor of Anatomy at U.T. Medical School, Galveston, TX.

Douglas A. Baxter. 1981. Mechanism of pre‑synaptic inhibition of transmitter release in crayfish axons. Senior Staff Scientist at Sensory Sciences Center, Baylor Medical School.

Rebecca Sheller. 1989. Molecular mechanisms for long term survival of severed crayfish nerve axons. Professor, Southwestern University, Georgetown, TX.

Shobhana Sivaramakrishnan. 1989. Biophysical mechanisms of calcium and membrane depolarization in synaptic facilitation. Research Scientist, University of Connecticut.

Alvin Lyckman. 1990. Mechanisms of neuritic outgrowth, neuritic guidance, and specific functional reconnection of severed giant axons in earthworms. Current address unknown.

Stephen Massia. 1992. Surface modifications of synthetic materials for the promotion of cell adhesion. Co-directed with Dr. Jeffrey Hubbel of Chemical Engineering. Research Scientist in a private biotechnology firm.

Jeffery Moehlenbruck. 1993. Biochemical mechanisms for long term survival of severed goldfish axons. Professor, St. Edwards Univeristy, Austin, TX.

Todd Krause. 1993. Cellular mechanisms for rapid repair of severed giant axons. Patent attorney, Boston, MA .

Sandy Tanner. 1994. Protein transport and turnover in crayfish medial gaint axons. Research Director, Nymox Corporation (retired)..

Sterling Wright. 1995. Biophysical/electrophysiological mechanisms of synaptic plasticities at crayfish neuromuscular junctions. Professor, Murray State University, Ky.

Tim Raabe. 1995. Mechanisms which determine protein turnover in intact and anucleate axons in vertebrates. Professor, St. Mary’s University, San Antonio, TX.

Curtis Herbert. 1996. Effect of inhibitors of fibrinogen proteolysis on neuritic outgrowth from dorsal root ganglia. Co-directed with Dr. Jeffrey Hubble of Chemical Engineering. Associate Professor, University of Minnesota, Minneapolis, Minn.

Chris Eddleman. 1999 Biophysics and molecular biology of plasmalemmal sealing. Co-directed with Dr. Harvey Fishman, UTMB Galveston. Currently a practicing MD

 Soonmoon Yoon. 2003 Molecular mechanisms of axonal sealing. Co-directed with Dr. Harvey Fishman. Current position unknown

 Michael Nguyen. 2006. Role of calcium in neurite sealing and cell degeneration. Co-directed with Dr. Harvey Fishman. Currently a practicing MD.

 Chris Spaeth. 2011. Molecular mechanisms of plasmalemmal sealing. Research Scientist, Houston

 Aleksej Zuzek. 2012. Biochemical pathways of plasmalemmal sealing. Postdoctoral Fellow at Texas A&M Medical School (Temple, TX)

Tyler Smith. 2021. Immunosuppressive Effects of PEG-fusion in Peripheral Nerve Allografts. Post-doctoral fellow with Dr. Jennifer Wu, Northwestern University

Cameron Ghergherehchi. 2021. Polyethylene glycol fusion repair of rat peripheral nerves. Post-doctoral fellow with Dr. Jaimie Shores. Johns Hopkins Medical School.

3. *Postdoctoral Fellows. Last known position.*

*Completed*

Dr. Thomas Hamilton, 1973 ‑ 1974. CIA biomedical scientist and Professor of Biology, University of Virginia, Falls Church.

Dr. Larry Sewell, 1973 ‑ 1974. Patent attorney and biomedical consultant, University of Texas Medical School, Dallas.

Dr. Samuel Velez, 1975 ‑ 1976. Professor of Biology, Dartmouth.

Dr. Bonnie Templeton, 1975 ‑ 1976. Research Associate, Washington University, Department of Biology, St. Louis, MO.

Dr. Thomas Anderson, 1977 ‑ 1979. Director of the CNS Trauma Research Center, General Motors Corp.

Dr. David Falk, 1978. Current position unknown.

Dr. Robert Grossfeld, 1976 ‑ 1979. Professor Emeritus of Zoology, North Carolina State University, Raleigh.

Dr. Douglas Baxter, 1981. Mechanism of pre-synaptic inhibition of transmitter release in crayfish axons. Senior Staff Scientist at Sensory Sciences Center, Baylor Medical School.

Dr. Terry A. Viancour, 1982 ‑ 1984. Professor of Zoology, University of Maryland, Baltimore.

Dr. Richard A. Friedman, 1983 ‑ 1985. Professor of Biophysics and Physiology, Vanderbilt University.

Dr. Kalpathi Seshan, 1982 ‑ 1986. Research Associate, MD Anderson.

Dr. Steven Halls, 1986 - 1987. Current position unknown.

Dr. Bruce Winegar, 1986 ‑ 1988. Research Associate, Department of Pharmacology, University of California Medical School, San Francisco, CA.

Dr. Scott Poehlman, 1988 - 1989. MD. Neurology, University of Wisconsin, Madison.

Dr. Alvin Lyckman, 1991 - 1992. Research Associate. NIH.

Dr. Jay Blundon, 1987 ‑ 1993. NIH, NIAAA postdoctoral fellowships. Professor, Department of Biology, Rhodes College, Memphis, TN.

Dr. Rebecca Sheller, 1990 - 1994. NIAAA postdoctoral fellowship. Professor at Southwestern University, Georgetown, TX.

Dr. Todd Krause, 1993 - 1994. NIAAA fellowship. Co-directed with Dr. Harvey Fishman (UTMB, Galveston) Dept of Biophysics. Patent attorney. Boston, MA..

Dr. Eric Detrait. 1998-2000. Molecular mechamims of plasmalemmal sealing. Co –directed with Dr. Fishman. Currently a Research Scientist at University of Rochester Medical School.

Dr. Ronda Stavisky. 2002-2005. Role of PEG in axonal repair. Current position unknown.

Dr. Van Herd. 2010-2013. Current position unknown.

Dr.Solomon Raju Bhupanapadu Sunkesula. 5/2013 – 12/2015. Role of PEG in axonal repair; Biochemical pathways of membrane sealing. Research Scientist, MD Anderson

Dr. Cameron Ghergherehchi. 6/2021-8/2021. Polyethylene glycol fusion repair of rat peripheral nerves. Post-doctoral fellow with Dr. Jaimie Shores. Johns Hopkins Medical School.

Dr, Tyler Smith. 6/2021-8/2021. Immunosuppressive Effects of PEG-fusion in Peripheral Nerve Allografts. Post-doctoral fellow with Dr. Jennifer Wu, Northwestern University

1. *RESEARCH SUPPORT:* G. Bittner = sole P.I. unless otherwise noted; direct costs. 55 years of continuous funding. **See Detailed Research Support for additional information.**

 **Current**

**DOD PRORP Grant** Immediate Repair With Accelerated Recovery From Peripheral Nerve Injury Using PEG-Fusion 9/19- 8/22 Subcontracts with Johns Hopkins Medical School (Dr. Jamie Shores, MD PI/PD) Baltimore, MD and Metis Foundation, Brooke Army Hospital SA,TX (Col. Eric Weitzel, MD PI/PD)

 $749,742: Direct Costs: $578,800 Indirect Costs: $170,942

 COVID-19 Supplement awarded to UTA 9/15/2020-8/2022

 $75,169: Direct Costs $48,031 Indirect Costs: $27,138

**DOD AFIRM Grant**. AFIRM III Award W81XWH2010825 "Polyethylene Glycol (PEG)-Mediated Fusion (PEG Fusion) Repair of Mixed Motor-Sensory Acute Peripheral Nerve Injuries (PNI) for Rapid and Immediate Improvement in Outcome" Multimodal approach to improve functional recovery following acute and delayed peripheral nerve injury (PNI) repair. J Alderete, RESTOR/ Metis Foundation San Antonio: Co-ordinating PI. G Bittner. Co-PI. Final funding under negotiation.

 12/2020-9/2025. ~$1,800,000. UT Austin ~$418,000 direct + indirect. 11/2021-9/2023

**Lone Star Paralysis Foundation Nerve Regeneration Research 1/06 - 8/19. Direct Costs**

6/11-12/12 $50,000

2/12- 12/13 $40,000-45,000 (eqpt and student training)

5/12-12/14 $60,000

5/14-12/15 $40,000 + eqpt

1/16-12/16 ~$60,000 + eqpt

1/16- 7/16 $20,000 Dr. Richard Trevino (PI) at WellSpan York Hospital and G Bittner (Basic science advisor) to U Pennsylvania Pharmaceutical lab for FDA IND of sterile PEG solution for York IRB

1/17-12/17 $60,000

 1/18- 8/30/19 30K (3/7/18 )+35K(5/22/18) +10K(8/6/18) +90K 8/30/18) = $165,000 9/2019-5/2020 $60,000

 5/2020 – 11/2021 $50,000 support basic research

 **CURRENT**

**1.Lone Star Paralysis Foundation grant**

 **Title.** Enhanced Regeneration and Repair of Severed Spinal Axons

 **Time Commitment:** 1% [0.12 person-months]

 **Agency:** Lone Star Paralysis Foundation

 **Grants Officer:** Doug English, 7900 FM 1826, Bldg. II Rm. 105, Austin, TX 78737

 **Performance Period and Funding: (Gift: all direct costs)** 3/2021 - 1/2024

$195,000 direct costs to support postdoctoral fellows on spinal research

 **Description/Aims:** The goal is to modify our PEG-fusion technology to repair spinal cord and PNS injuries. As a gift, all funds are direct costs only with no overhead costs to support pilot studies in basic research with no specific Aims

**2. DOD PRORP Grant**

**Title: W81XWH-19-2-0054. Log # OR180077.** Immediate repair with accelerated recovery from peripheral nerve injury using PEG-fusion technologies

 **Time Commitment:** 10% [1.2 person-months]

 **Agency:** DOD PRORP grant

 **Grants Officer:** Miriam Redington, Science Officer;301.619.3477 Miriam.E.Redington.CIV@mail.mil

 **Performance Period and Funding:** 9/15/2019 – 9/14/2022. $ 824,911 total costs. G Bittner submitting and corresponding PI. $510,046 total costs to UTA, $188,988 to Johns Hopkins Medical School (Jaimie Shores PI), and $114,877 To DOD METIS (Erik Weitzel, PI, Joseph Alderete Key Collaborator).

 **Description/Aims:** Pilot study to determine the possible efficacy of PEG-fusion technology on single transection peripheral nerve injuries (PNIs) repaired by primary PEG-fusion and segmental loss (ablation type) PNIs repaired by PEG-fused allografts in rats and swine.

**3. DOD AFIRM III granny**

**Title: W81XWH2020029. Multimodal approach to improve functional recovery following acute and delayed nerve repair [for single transections repaired by PEG-fused neurorrhaphy and segmental loss ablations repaired by PEG-fused *auto*grafts]**

**Role:** PI: UT-Austin site on subcontract to SA (Joe Alderete, PI)

 **Time Commitment:** 10% [1.20 person-months]

 **Agency:** DOD AFIRM III grant

 **Grants Officer: Raul Corpus**

 **Performance Period and Funding:** 10/1/2021 - 09/30/2023; $264,534 direct costs, $419,286 total costs for UTA Subcontract Site Project Total. Subcontract for AFIRM III grant funded for about $1,800,000 to Joseph Alderete, PI for AFIRM III application also by Jamie Shores (JHU) for about $6,000,000 for clinical trials of single transections repaired by PEG-fused neurorrhaphy and segmental loss ablations repaired by PEG-fused *auto*grafts.

**Description.** UTA subcontract to train SA surgeons in PEG-fusion and to examine some specific aspects of PEG-fusion in singly transected PNIs repaired by neurorrhaphy and segmental loss PNAs repaired by isograft PNAs.

**SUBMITTED PROPOSALS**

**1**. **NIH R-01 Proposal**.

**Title:** Localized Immunosuppression and Axonal Fusion Best Repair Segmental DefectsJared Bushman submitting and overall PI at U. Wyoming (Laramie), George Bittner Subcontract PI at U. Texas (Austin)

 **Time Commitment:** 10% [1.2 person-months]

 **Agency:** NIH

 **Grants Officer:** TBD

 **Performance Period and Funding:** 9/1/2022- 8/31/2027.About $2,800,000 total. Austin subcontract about $1,000,000

 **Description/Aims:**.

We propose to develop and merge two complimentary methods that *each enhance recovery after ablation PNIs superior to current best clinical practices*. Our hypotheses and goals are that combining these methods will result in a new standard of care with *significantly improved and faster functional return* following ablation PNIs. Both methods use live (not decellularized) donor peripheral nerve allografts (**PNA**s) as a bridging device. *The first complementary method applies a precise series of solutions (one of which is poly(ethylene glycol) (****PEG****) during surgery to non-selectively fuse donor axons to host axons at proximal and distal ends of the PNA.* *The second complementary method provides immune suppression localized only to the PNA, leaving the immune system unaffected in the rest of the body.*

**2. 2022 DOD PRORP Proposal**

**Title: Peripheral nerve segmental-loss injuries repaired with polyethylene glycol (PEG)-fused allografts**

 PI G. Bittner at U. Texas (Austin). Subcontract PIs: Jaimie Shores MD, JHU Baltiomore, MD; Col. Joseph Alderete MD, RESTOR, SanAntonio

 **Time Commitment:** 10% [1.2 person-months]

 **Agency:** DOD

 **Grants Officer:** TBD

 **Performance Period and Funding:** 9/15/2023- 9/14/2025.About $725,000 total. Austin subcontract about $400,000

 **Description/Aims:**. **Impact, Focus Area, and Areas of Encouragement of this proposal:** *Return to Duty:* PEG-fused VPNAs would facilitate nerve repair at a combat support hospital (*intra-theatre*) and more rapidly return injured service members to duty than is currently possible with any other current clinical procedure. More specifically, ourapplied research objectives provide critical data to advance this emerging technology toward clinical trials. *In rat and swine model systems, we propose to confirm preliminary data for PEG-fused Viable Peripheral Nerve Allografts (VPNAs) that:* **Aim 1.1:** VPNAs need not be tissue matched or immune suppressed no matter the immunological mismatch between host and donor. **Aim 1.2**: The length of the ablation PNI or VPNA does not alter functional recovery. **Aim 1.3:** VPNA repair of segmental loss PNIs can be delayed post-injury for at least 36h by using VPNAs that are stored for at least 36h. **(Aim 2)**. Recovery benefits of PEG-fused VPNAs demonstrated by in rats as a small animal model can be translated to a larger animal model (swine) as the next logical step toward clinical translation.

**3. 2022 DOD RTRP Proposal**

**Title: A multi-modal approach to reduce VCA immunogenicity and improve functional outcome**

 PI. G. Bittner at U. Texas (Austin). Subcontract PIs: Jaimie Shores MD, JHU Baltiomore, MD; Col. Joseph Alderete MD, RESTOR, SanAntonio

 **Time Commitment:** 10% [1.2 person-months]

 **Agency:** DOD

 **Grants Officer:** TBD

 **Performance Period and Funding:** 9/30/2023- 9/29/2025.About $1,500,000 total. Austin subcontract about $650,000

**Description/Aims:** Vascularized composite allografts (VCAs) are a powerful biologic option that could restore may lost functions after composite tissue losses for many military or civilian personnel living with limb loss. Use of VCAs to restore limb loss is severely hampered by deleterious interactions between (1) loss of blood and lymph flow; (2) prolonged muscle denervation causing much muscle atrophy and loss of blood flow by muscle inactivity; and, (3) prolonged sensory denervation causes atrophy of sensory nerve endings and organs that combined with (1) and (2) above increase the probability and extent of traumatic injuries to the VCA after transplantation. For this RTRP application, we propose to significantly reduce the impact of these three deleterious processes increasing VCA immunogenicity by using two novel technologies has recently developed: (1) rapid (within minutes) and permanent repair/joining of severed nerves in transplanted limbs using our polyethylene glycol repair (PEG-fusion) technology to increase blood flow and decrease motor-sensory atrophy and (2) applying methyl prednisolone (MP) as a localized immune-suppressant (ISN) technology at sites of PEG-fusion. Hence,  *in rat model systems, we propose to use hind limb VCAs to show that:* Aim 1: PEG-fused severed nerves in autologous transplants (remove and re-attach same limb) and no systemic ISN produce significantly better outcomes than autologous transplants without PEG-fusion and no systemic ISN. Aim 2: Allogenic transplants with PEG-fusion of severed nerves plus systemic ISN with FK506 produce significantly better outcomes than allogenic transplants without PEG-fusion and systemic ISN. Aim 3: Autologous and allogenic transplants with PEG-fusion of severed nerves plus systemic ISN with FK506 and localized ISN using MP produce significantly better outcomes than autologous or allogenic transplants with PEG-fusion and systemic ISN, but no localized ISN, respectively.

**4. UTA POC matching proposal**

**Title: NOVEL PEG-FUSION THERAPY FOR ACUTE AND CHRONIC SPINAL CORD INJURY (SCI)**

 PI. G. Bittner at U. Texas (Austin).

 **Time Commitment:** NA

 **Agency:** UT and commercial or foundation partner (Neuraptive Inc or LSPF)

 **Grants Officer:** TBD

 **Performance Period and Funding:** 12/1/2023- 11/30/2022. $250,000 plus at least $125,000 in direct costs for two subsequent years

**Description/Aims:** **Q1 Q2 Q3 Q4 Budget**

N. *PUBLICATIONS AND CONTRIBUTIONS*

J. Chen, K.F. Killam, and G.D. Bittner. 1964. Comparison of chlorpromazine, trifluoperazine and pentobarbital on conditioned arousal to reticular stimulation in cats. Fed. Proc. 23:264‑268.

G.D. Bittner. 1967. Excitation‑contraction coupling in crustacean neuromuscular systems. Ph.D. Thesis. Stanford University.

R.R. Hoy, G.D. Bittner, and D. Kennedy. 1967. Regeneration in crustacean motoneurons: evidence for axonal fusion. Science 156:251‑252.

G.D. Bittner. 1968. The differentiation of crayfish muscle fibers during development. J. Exp. Zool. 167:439‑456.

G.D. Bittner. 1968. Differentiation of nerve terminals in the crayfish opener muscle and its functional significance. J. Gen. Physiol. 51:731‑758.

G.D. Bittner and D. Kennedy. 1970. Quantitative aspects of transmitter release. J. Cell. Biol. 47:585‑590.

G.D. Bittner and J. Harrison. 1970. A reconsideration of the Poisson Hypothesis for transmitter release at the crayfish neuromuscular junction. J. Physiol. 206:1‑23.

H.L. Atwood and G.D. Bittner. 1971. Matching of excitatory and inhibitory inputs to crustacean muscle fibers. J. Neurophysiol. 34:157‑170.

H.L. Atwood, C.K. Govind, and G.D. Bittner. 1973. Ultrastructure of nerve terminals and muscle fibers in denervated crayfish muscle. Zeit. Zellforsch. 146:155‑166.

G.D. Bittner and R. Kopanda. 1973. Factors influencing molting in the crayfish *Procambarus clarkii*. J. Exp. Zool. 186:7‑17.

G.D. Bittner. 1973. Trophic dependence of fiber diameter in a crustacean muscle. Exp. Neurol. 41:38‑53.

G.D. Bittner. 1973. Degeneration and regeneration in crustacean neuromuscular systems. Amer. Zool. 13:379‑408.

G.D. Bittner and A. Johnson. 1974. Degeneration and regeneration in crustacean peripheral nerves. J. Comp. Physiol. 89:1‑21.

L.P. Boone and G.D. Bittner. 1974. Morphological and physiological measures of trophic dependence in a crustacean muscle. J. Comp. Physiol. 89:123‑144.

G.D. Bittner, M. Ballinger, and J.L. Larimer. 1974. Crayfish CNS: minimal degenerative‑regenerative changes after lesioning. J. Exp. Zool. 189:13‑36.

M.P. Charlton and G.D. Bittner. 1974. Facilitation of transmitter release at the squid giant synapse. Biol. Bull. 147:471‑472.

D. Kennedy and G.D. Bittner. 1974. Ultrastructural correlates of motor nerve regeneration in the crayfish. Cell Tiss. Res. 148:97‑110.

G.D. Bittner and M. Nitzberg. 1975. Degeneration of sensory and motor axons in transplanted segments of a crustacean peripheral nerve. J. Neurocytol. 4:7‑21.

G.D. Bittner and D.W. Mann. 1976. Differential survival of isolated portions of crayfish axons. Cell and Tiss. Res. 169:301‑311.

S.C. Birse and G.D. Bittner. 1976. Regeneration of giant axons in earthworms. Brain Res. 113:575‑581.

G.D. Bittner and L. Sewell. 1976. Facilitation at crayfish neuromuscular junctions. J. Comp. Physiol. 109:287‑308.

G.D. Bittner. 1977. Trophic interactions of crustacean neurons. In: Identified Neurons and Behavior, Ed. by G. Hoyle in honor of Professor C.A.G. Wiersma. pp. 507‑532.

M.L. Ballinger and G.D. Bittner. 1978. Developmental abnormalities of identifiable neurons in the crayfish *Procambarus simulans*. J. Neurobiol. 9:301‑307.

G.D. Bittner and D.L. Traut. 1978. Growth of crustacean muscles: constancy of fiber number and sarcomere number. J. Comp. Physiol. 124:277‑285.

M.P. Charlton and G.D. Bittner. 1978. Effect of changes in presynaptic potentials on facilitation in squid synapses. J. Gen. Physiol. 72:487‑511.

M.P. Charlton and G.D. Bittner. 1978. Facilitation of transmitter release at squid synapses. J. Gen. Physiol. 72:471‑486.

M.R. Meyer and G.D. Bittner. 1978. Histological studies of trophic interactions in crayfish giant axons. Brain Res. 143:195‑211.

M.R. Meyer and G.D. Bittner. 1978. Biochemical studies of trophic interactions in crayfish giant axons. Brain Res. 143:212‑232.

M.L. Ballinger and G.D. Bittner. 1980. Ultrastructural studies of severed medial giant and other CNS axons in crayfish. Cell and Tiss. Res. 208:123‑133.

G.D. Bittner and M.L. Ballinger. 1980. Ultrastructural changes at gap junctions between lesioned crayfish axons. Cell and Tiss. Res. 207:143‑153.

D.A. Baxter and G.D. Bittner. 1980. The normal accumulation of facilitation during presynaptic inhibition. Brain Res. 189:535‑539.

T.E. Anderson and G.D. Bittner. 1980. Long‑term alteration of electrotonic synapses. Brain Res. 184:224‑228.

C.E. Hulsebosch and G.D. Bittner. 1980. Evolution of abilities to regenerate CNS neurons. Am. Naturalist 115:276‑284.

T.A. Viancour, G.D. Bittner and M.L. Ballinger, 1981. Selective transfer of Lucifer Yellow CH from axoplasm to adaxonal glia. Nature. 293:65‑67.

M.S. Bouton and G.D. Bittner. 1981. Regeneration of motor axons in crayfish limbs: distal stump activation followed by synaptic reformation. Cell and Tiss. Res. 219:379‑392.

G.D. Bittner and M.R. Brown. 1981. Long term survival of enucleated glial cytoplasm in the leech *Macrobdella decora*. Brain Res. 218:357‑364.

C.E. Hulsebosch and G.D. Bittner. 1981. Regeneration of nerve cell bodies in annelids: a test of the neuronal addition hypothesis. J. Comp. Neurol. 198:77‑88.

C.E. Hulsebosch and G.D. Bittner. 1981. Morphology and number of neurons in two species of polychaetes. J. Comp. Neurol. 198:65‑76.

S. Velez, G.D. Bittner, G.K. Govind and H.L. Atwood. 1981. Trophic reactions of crayfish muscle fibers and nerve synapses following denervation, tenotomy, and immobilization. Exp. Neurol. 71:307‑325.

S.C. Birse and G.D. Bittner. 1981. Regeneration of earthworm giant axons following transection or ablation. J. Neurophysiol. 45:724‑742.

G.D. Bittner and R.A. Schatz. 1981. An examination of the residual calcium hypothesis for transmitter release. Brain Res. 210:431‑436.

G.D. Bittner. 1981. Trophic interactions of crustacean giant axons. Comp. Biochem. Physiol. 68A:299‑306.

R.M. Grossfeld, G.D. Bittner, and M.A. Raymond. 1982. Inter‑ and intra‑axonal variations in morphology and metabolic activity of the crayfish medial giant axon. J. Neurobiol. 13:191‑197.

D.A. Baxter and G.D. Bittner. 1982. Intracellular recordings from crustacean motor axons during presynaptic inhibition. Brain Res. 223:422‑428.

G.D. Bittner. 1983. Muscles and their neural control. Science 222:611‑613.

D.A. Baxter, G.D. Bittner, and T.H. Brown. 1985. Quantal mechanisms of long‑term synaptic potentiation. PNAS 82:5978‑5982.

G.D. Bittner, and J.P. Segundo. 1986. Facilitation. In Encyclopedia of Neuroscience. Ed. G. Adelman. Birkhauser. p. 428-430.

G.D. Bittner, M.L. Ballinger, and M.A. Raymond. 1986. Reconnection of severed nerve axons with polyethylene glycol. Brain Res. 367:351‑365.

K.R. Seshan and G.D. Bittner. 1987. Developmental and other factors affecting regeneration of crayfish CNS axons. J. Comp. Neurol. 262:535-545.

T.A. Viancour, K.R. Seshan, G.D. Bittner, and R.A. Sheller. 1987. Organization of axoplasm in crayfish giant axons. J. Neurocytol. 16:557-566.

R.N. Friedman, G.D. Bittner, and J.A. Blundon. 1988. Electrophysiological and behavioral effects of ethanol on crayfish. J. Exp. Pharm. & Therap. 246:125-131.

G.D. Bittner. 1988. Long term survival of severed distal axonal stumps in vertebrates and invertebrates. Am. Zool. 28:1165-1179.

B.D. Winegar, G.D. Bittner, and S.W. Leslie. 1988. Effects of pentobarbital on behavioral and synaptic plasticities in crayfish. Brain Res. 475:21-27.

T.A Viancour, R.A. Sheller, G.D. Bittner, and K.R. Seshan. 1988. Protein transport between crayfish lateral giant axons. Brain Res. 439:211-221.

G.D. Bittner and J.P. Segundo. 1989. Effect of stimulus timing on transmitter release and postsynaptic membrane potential at crayfish neuromuscular junctions. J. Comp. Physiol. 165:371-382.

G.D. Bittner. 1989. Synaptic plasticity at the crayfish opener neuromuscular preparation. J. Neurobiol. 20:386-408.

J.A. Blundon, R.A. Sheller, J.W. Moehlenbruck, and G.D. Bittner. 1990. Effect of temperature on long term survival of anucleate giant axons in crayfish and goldfish. J. Comp. Neurol. 297:377-391.

T.L. Krause and G.D. Bittner. 1990. Rapid morphological fusion of severed myelinated axons by polyethylene glycol. PNAS. 87:1471-1475.

S. Sivaramakrishnan, G.D. Bittner, and M.S. Brodwick. 1991. Calcium-activated potassium conductance in presynaptic terminals at crayfish neuromuscular junction. J. Gen. Physiol. 98:1161-1180.

S. Sivaramakrishnan, M.S. Brodwick, and G.D. Bittner. 1991. Presynaptic facilitation at crayfish neuromuscular junctions: role of calcium-activated potassium conductance. J. Gen. Physiol. 98:1181-1196.

R.A. Sheller, M.L. Ballinger, and G.D. Bittner. 1991. Long term survival of severed crayfish giant axons is not associated with an incorporation of glial nuclei into axoplasm. Neurosci. Letters 133:113-116.

T.L. Krause, R.M. Marquis, A.W. Lyckman, M.L. Ballinger, and G.D. Bittner. 1991. Rapid artificial restoration of electrical continuity across a crush lesion of a giant axon. Brain Res. 561:350-353.

G.D. Bittner. 1991. Long term survival of anucleate axons and its implications for nerve regeneration. Trends in Neurosci. 14:188-193.

G.D. Bittner and D.A. Baxter. 1991. Mechanisms of synaptic plasticity at crayfish neuromuscular junctions: facilitation and augmentation. Synapse. 7:235-243.

D.A. Baxter and G.D. Bittner. 1991. Mechanisms of synaptic plasticity at crayfish neuromuscular junctions: pre-synaptic inhibition. Synapse 7:244-251.

A.W. Lyckman and G.D. Bittner. 1992. Axonal conduction and electrical coupling in regenerating earthworm giant axons. Exp Neurol. 117:299-306.

R.A. Sheller and G.D. Bittner. 1992. Maintenance and synthesis of proteins for an anucleate axon. Brain Res. 580:68-80.

A.W. Lyckman, S.M. Thomas and G.D. Bittner. 1992. Analysis of neuritic outgrowth from severed giant axons in *Lumbricus terrestris*. J. Comp. Neurol. 318:426-438.

J.A. Blundon and G.D. Bittner. 1992. Effects of ethanol and other drugs on excitatory and inhibitory neurotransmission in the crayfish. J. Neurophysiol. 67:576-587.

J.A. Blundon, S.N. Wright, M.S. Brodwick and G.D. Bittner. 1993. Residual free calcium is not responsible for facilitation of transmitter release. PNAS 90:9388-9392.

R.A. Sheller and G.D. Bittner. 1993. Whole intact tissue electrophoresis of nerve proteins. J. Neurosci. Methods 49:185-191.

J.W. Moehlenbruck, J.A. Cummings and G.D. Bittner. 1994. Long term survival followed by degradation of neurofilament proteins in severed Mauthner axons of goldfish. J. Neurobiol. 25:1637-1651.

T.L. Krause, H.M. Fishman, M.L. Ballinger, and G.D. Bittner. 1994. Extent and mechanism of sealing in transected giant axons of squid and earthworms. J. Neurosci. 14:6638-6651.

T.L. Krause, H.M. Fishman, and G.D. Bittner. 1994. Axolemmal and septal conductance in the impedance of the earthworm medial giant nerve fiber. Biophys. J. 67:692-695.

M.A. Todora, H.M. Fishman T.L. Krause, and G.D. Bittner. 1994. Shortening of a severed squid giant axon is non-uniform and occurs in two phases. Neurosci. Lett. 179:57-59.

T.L. Krause, Y. Magarshak, H.M. Fishman, and G.D. Bittner. 1995. Membrane potential and input resistance are ambiguous measures of sealing of transected cable-like structures. Biophys. J. 68:795-799.

S.L. Tanner, E.E. Storm, and G.D. Bittner. 1995. Protein transport in intact and severed (anucleate) crayfish medial giant axons. J. Neurochem. 64:1491-1501.

R.A. Sheller, M. Tytell, M. Smyers, and G.D. Bittner. 1995. Glia to axon communication: Enrichment of glial proteins transferred to the squid giant axon. J. Neurochem. Res. 41:324-334.

S.L. Tanner, E.E. Storm, and G.D. Bittner. 1995. Maintenance and degradation of proteins in intact and severed axons: Implications for the mechanism of long term survival of anucleate crayfish axons. J. Neurosci. 15:540-548.

T.D. Raabe, T. Nguyen, and G.D. Bittner. 1995. Calcium activated proteolysis of neurofilament proteins in goldfish Mauthner axons. J. Neurobiol. 26:253-261. PubMed PMID: 7707045.

J.A. Blundon, S.N. Wright, M.S. Brodwick, and G.D. Bittner. 1995. Presynaptic calcium-activated potassium channels and calcium channels at a crayfish neuromuscular synapse. J. Neurophysiol. 73:178-189.

T. Sea, M.L. Ballinger, and G.D. Bittner. 1995. Cooling of peripheral myelinated axons retards Wallerian degeneration. Exp. Neurol. 133:85-95.

C.S. Eddleman, C.M. Godell, H.M. Fishman, M. Tytell, and G.D. Bittner. 1995. Florescent labelling of the glial sheath of giant nerve fibers. Biol. Bull., 189:218-219.

H.M. Fishman, T.L. Krause, A.L. Miller, and G.D. Bittner. 1995. Retardation of the spread of extracellular Ca++ into transected, unsealed squid giant axons. Biol. Bull., 189:208-209.

T.D. Raabe and G.D. Bittner. 1996. Phosphorylation of neurofilament proteins in isolated goldfish Mauthner axoplasm. J. Neurochem., 66:1214-1221.

C.B. Herbert, G.D. Bittner, and J. A. Hubbell. 1996. Effects of fibrinolysis on neurite growth from dorsal root ganglia cultured in two- and three-dimensional fibrin gels. J. Comp. Neurol., 365:380-391. doi: 10.1002/(SICI)1096-9861(19960212)365:3<380::AID-CNE4>3.0.CO;2-0. PubMed PMID: 8822177.

T.D. Raabe, T. Nguyen, C. Archer, and G.D. Bittner. 1996. Mechanisms for the maintenance and eventual degradation of neurofilament proteins in the distal segments of severed goldfish Mauthner axons. J. Neurosci., 16: 1605-1613. PubMed PMID: 8774429.

S.N. Wright, M.S. Brodwick, and G.D. Bittner. 1996. Presynaptic calcium currents at voltage- clamped excitor and inhibitor terminals of crayfish. J. Physiol., 496:347-361. PubMed PMID: 8910221; PubMed Central PMCID: PMCPMC1160882.

S.N. Wright, M.S. Brodwick, and G.D. Bittner. 1996. Calcium currents, transmitter release and facilitation of release at voltage-clamped crayfish nerve terminals . J. Physiol. ,496:361-378. PubMed PMID: 8910222; PubMed Central PMCID: PMCPMC1160883

O. Weiner, A.M. Zorn, P.A. Krieg, and G.D. Bittner.1996 Medium-weight neurofilament mRNA in goldfish Mauthner axoplasm. Neurosci. Letters, 213: 83-86. PubMed PMID: 8858614; PubMed Central PMCID: PMCPMC2830807.

A. Sunio and G.D. Bittner. 1997. Cyclosporin retards the Wallerian degeneration of peripheral mammalian axons. Exp. Neurol., 146:46 - 56. doi: 10.1006/exnr.1997.6484. PubMed PMID: 9225737.

C.S. Eddleman, M.L. Ballinger, M.E. Smyers, C.M. Godell, H.M. Fishman, and G.D. Bittner. 1997. Repair of plasmalemmal lesions by vesicles. PNAS. 94:4745-4750. PubMed PMID: 9114062; PubMed Central PMCID: PMCPMC20795.

C.M. Godell, M. Ballinger, C.S. Eddleman, M.E. Smyers, H.M. Fishman, and G.D. Bittner. 1997. Calpain promotes the sealing of severed giant axons. PNAS. 94:4751-4756. PubMed PMID: 9114063.

M.L. Ballinger, A.R. Blanchette, T.L. Krause, M.E. Smyers, H.M. Fishman, and G.D. Bittner. 1997 Delaminating myelin membranes help seal the cut ends of severed earthworm giant axons. J. Neurobiol., 33: 945-960. PubMed PMID: 9407015.

C.B. Herbert, C. Nagaswami, G.D. Bittner, J.A. Hubbell, and J.W. Weisel. 1998. Effects of fibrin

 micro-morphology on neurite growth from dorsal root ganglia cultured within three- dimensional fibrin gels. J. Biomed. Materials Res., 40: 551-559. PubMed PMID: 9599031

R.A. Sheller, M.E. Smyers, R.M. Grossfeld, M.L. Ballinger, and G.D. Bittner. 1998. Heat shock proteins in crayfish medial giant axons: High constitutive levels and transfer of inducible isoforms from glia. J. Comp. Neurol. 396:1-11. PubMed PMID: 9623883.

C.S. Eddleman, M.L. Ballinger, M.E. Smyers, H.M. Fishman, and G.D. Bittner. 1998. Endocytotic formation of vesicles and other membranous structures induced by Ca2+ and axoplasmic injury. J. Neurosci. 18:4029-4041. PubMed PMID: 9592084.

C.S. Eddleman, M.E. Smyers, A.Lore, H.M. Fishman and G.D. Bittner. 1998. Anomalies associated with dye exclusion as a measure of axolemmal repair. Neurosci. Letters. 256: 123-126. PubMed PMID: 9855355.

A.B.Lore, J.A.Hubbell, D.S. Bobb Jr., M.L.Ballinger, K.L. Loftin, , J.W.Smith, M.E. Smyers, H.D.Garcia and G.D. Bittner. 1999. Rapid induction of functional and morphological continuity between severed ends of mammalian or earthworm myelinated axons. J Neurosci. 19: 2442 – 2454. PubMed PMID: 10087059.

A.R. Blanchette, M.L. Ballinger, H.M. Fishman, and G.D. Bittner. 1999. Calcium entry initiates processes that restore a barrier to dye entry in severed earthworm axons. Neuroscience Letters. 272:147-150. PubMed PMID: 10505602.

G.D. Bittner, T. Schallert, and J. D. Peduzzi. 2000. Degeneration, trophic interactions, and repair of severed axons: A reconsideration of some common assumptions. The Neuroscientist. 6: 88 - 109. .

G.D. Bittner and H.M. Fishman. 2000. Axonal sealing following injury. Invited chapter in Nerve Regeneration. Ed. N. Ingoglia and M. Murray. Marcel Dekker. P. 337 - 370

G.D. Bittner and B.X. Friedman. 2000. Evolution of brain structures and adaptive behaviors in humans and other animals: role of polymorphic genetic variations. The Neuroscientist. 6: 241 - 251

 J. W. Lichstein, M.L. Ballinger, A.R. Blanchette, H.M. Fishman, and G.D. Bittner. 2000. Structural changes at the cut ends of earthworm giant axons in the interval between dye barrier formation and neuritic outgrowth. J. Comp. Neurol. 416: 143-157. PubMed PMID: 10581462 .

C.S. Eddleman, E. Detrait, G.D. Bittner, and H.M. Fishman. 2000. Barrier permeability at cut axonal ends progressively decreases until an axonal seal is formed. Biophys. J., 79: 1883 - 1890. . doi: 10.1016/S0006-3495(00)76438-1. PubMed PMID: 11023894; PubMed Central PMCID: PMCPMC1301080.

E. Detrait, C.S. Eddleman, S. Yoo, M. Fukuda, G.D. Bittner, and H.M. Fishman. 2000. Axolemmal repair requires proteins that mediate synaptic vesicle fusion. J. Neurobiol. 44:382 - 391. PubMed PMID: 10945894.

E. Detrait, S. Yoo, C.S. Eddleman, M. Fukuda, G.D. Bittner, and H.M. Fishman. 2000. Repair of severed neurites of PC 12 cells requires divalent cations and a conserved region of synaptotagmin. J. Neuroscience Research. 62: 566 – 573. PubMed PMID: 11070500.

T. C. Marzullo, J.S. Britt, R. Stavisky, and G. D. Bittner. 2001. Cooling enhances in vitro survival and fusion-repair of severed axons taken from the peripheral and central nervous system of rats. Neuroscience Letters. 327: 9-12. PubMed PMID: 12098488.

C.Z. Yang and G.D. Bittner. 2002. Effects of some dietary phytoestrogens in animal studies: review of a confusing landscape. Lab Anim (NY). 2002;31(9):43-8. doi: 10.1038/5000192. PubMed PMID: 12271330

C.S. Eddleman, G.D. Bittner, and H.M. Fishman. 2003. SEM comparison of severed ends of giant axons isolated from squid (*Loligo pealei*) and crayfish (*Procambarus clarkii*). Biol Bull. 203: 219 – 220. PubMed PMID: 12414587.

H.M. Fishman and G.D. Bittner. 2003. Vesicle-mediated restoration of a plasmalemmal barrier in severed axons. News in Physiological Sciences. 18:115-118. PubMed PMID: 12750447.

S. Yoo, M. P. Nguyen, M. Fukuda, G. D. Bittner, and H. M. Fishman. 2003. Plasmalemmal sealing of transected mammalian neurites is a gradual process mediated by Ca-regulated proteins. J. Neurosci. Res. 74:541-551. doi: 10.1002/jnr.10771. PubMed PMID: 14598298

R. C. Stavisky, J. M. Britt, T. Pham, T. C. Marzullo and G. D. Bittner. 2003. Wallerian Degeneration of mammalian PNS and CNS axons is accelerated by incubation with protein synthesis inhibitors. Neuroscience Res. 47: 445 – 449. doi: 10.1006/exnr.1997.6484. PubMed PMID: 9225737.

S. Yoo, J.E, Bottenstein, G. D. Bittner, and H. M. Fishman. 2004. Survival of mammalian B104 cells following neurite transection at different locations depends on somal calcium concentration. J. Neurobiol. 60: 137-153. doi: 10.1002/neu.20005. PubMed PMID: 15266646

R.C. Stavisky, J.M. Britt, A. Zuzek, E. Truong and G.D. Bittner. 2005. Melatonin enhances the *in vitro* and *in viv*o repair of severed rat sciatic axons. Neurosci. Letters, 376:98-101. doi: 10.1016/j.neulet.2004.11.033. PubMed PMID: 15698928.

M.G. Nguyen, G.D. Bittner, and H.M. Fishman. 2005. Critical interval of somal calcium transient after neurite transaction determines B104 cell survival. J. Neurosci. Res.,81: 805-816. doi: 10.1002/jnr.20606. PubMed PMID: 16049977; PubMed Central PMCID: PMCPMC1237108.

J.M. Britt, J.R. Kane, C.S. Spaeth, A. Zuzek, G.L. Robinson, M.Y. Gbanaglo, C.J. Estler, E.A. Boydston, T. Schallert and G.D. Bittner. 2010. Polyethylene glycol rapidly restores axonal integrity and improves the rate of motor behavior recovery after sciatic nerve crush injury. J Neurophysiol. 104: 695-703. doi: 10.1152/jn.01051.2009. PubMed PMID: 20445038.

C.S. Spaeth, E.A. Boydston, L.A. Figard, A. Zuzek and G.D. Bittner. 2010. A model for sealing plasmalemmal damage in neurons and other eukaryotic cells. J. Neurosci. 30:15790-15800. doi: 10.1523/JNEUROSCI.4155-10.2010. PubMed PMID: 21106818.

C. Z. Yang, S. I. Yaniger, V. C. Jordan, D. Klein and G.D. Bittner. 2011. Most Plastic Products Release Estrogenic Chemicals: A Potential Health Problem That Can Be Solved. Environmental Health Perspectives 119: 989-996. doi: 10.1289/ehp.1003220. Epub 2011 Mar 2

C.S. Spaeth, J.D. Fan, E.B. Spaeth, T. Robison, R.W. Wilcott and G.D. Bittner. 2012. Neurite transection produces cytosolic oxidation which enhances plasmalemmal repair. J Neurosci Res.90:945-954. doi: 10.1002/neu.20005. PubMed PMID: 15266646.

C.S. Spaeth, E.B. Spaeth, R.W.Wilcott, J.D.Fan, T.Robison and G.D. Bittner. 2012. Pathways for plasmalemmal repair mediated by PKA, Epac and cytosolic oxidation in rat B104 cells *in vitro* and rat sciatic axons *ex vivo*. Devel Neurol. 72:1399-1414. doi: 10.1002/dneu.20998. PubMed PMID: 22076955.

C.S. Spaeth, T.Robison, J.D.Fan and G.D. Bittner. 2012. Cellular mechanisms of plasmalemmal sealing and axonal repair by polyethylene glycol and methylene blue. J Neursosci Res. 90:955-966. doi: 10.1002/jnr.23022. PubMed PMID: 22302626.

G.D. Bittner, C.P. Keating, J. R. Kane, J.M. Britt, C.S. Spaeth,, J. D. Fan, A. Zuzek R.W. Wilcott, W. P. Thayer, J.M. Winograd, F. Gonzalez-Lima and T. Schallert. 2012. Rapid, effective and long-lasting behavioral recovery produced by microsutures, methylene blue and polyethylene glycol after complete cut of rat sciatic nerves. J Neurosci Res. 90:967-980. doi: 10.1002/jnr.23023. PubMed PMID: 22302646.

K.W. Sexton, A.C. Pollins, N. L. Cardwell, G. A. Del Corral, G. D. Bittner, R. B. Shack, L. B. Nanney, W. P. Thayer. 2012. Hydrophilic polymers enhance early functional outcomes after nerve autografting. J. Surgical Res. 177:392-400. doi: 10.1016/j.jss.2012.03.049. PubMed PMID: 22521220; PubMed Central PMCID: PMCPMC4096106.

A. Zuzek, J.D. Fan, C. S. Spaeth, G.D. Bittner. 2013. Sealing of transected neurites of rat B104 cells requires a diacylglycerol PKC-dependent pathway and a PKA-dependent pathway. Cell Molec Neurosci. 33:31-46. doi: 10.1007/s10571-012-9868-5. Epub 2012 Aug 3.

C.L. Rodriguez-Feo, K.W. Sexton,R. B. Boyer, A. C. Pollins,N. L. Cardwell, L. B. Nanney,R. B. Shack, M. A. Mikesh,C. H. McGill, C. W. Driscoll, G. D. Bittner, W. P. Thayer. 2013. Blocking the P2X7 Receptor Improves Outcomes After Axonal Fusion. J. Surgical Research. 184(1):705-13. doi: 10.1016/j.jss.2013.04.082. PubMed PMID: 23731685; PubMed Central PMCID:.

C.Z. Yang, W. Casey, M. Stoner, G.J .Kollessery, A.W. Wong and G.D. Bittner, 2014. A robotic MCF-7:WS8 cell proliferation assay to detect agonist and antagonist estrogenic activity. Toxological Sci. 137:335-349. doi: 10.1093/toxsci/kft250. PubMed PMID: 24213142; PubMed Central PMCID: PMCPMC3908721.

S.L. Myers, C.Z.Yang, G.D. Bittner, K.L. Witt, R.R. Tice, D.D. Baird. 2014. Estrogenic and Anti-Estrogenic Activity of Off –The-Shelf Hair and Skin Products. Journal of Exposure Science and Environmental Epidemiology. 25:271-277. doi: 10.1038/jes.2014.32. PubMed PMID: 24849798.

M.A.Stoner, C.Z.Yang, and G.D.Bittner. 2014. A Robotic BG1Luc Reporter Assay to Detect Estrogen Receptor Agonists. Toxicology in Vitro. 28: 916–925. . doi: 10.1016/j.tiv.2014.03.013. PubMed PMID: 24747293; PubMed Central PMCID: PMCPMC4088324

G.D.Bittner, M. A. Stoner, C. Z. Yang. 2014. Estrogenic chemicals often leach from BPA-free plastic products that are replacements for BPA-containing polycarbonate products. Environmental Health 13:41-54. doi: 10.1186/1476-069X-13-41. PubMed PMID: 24886603; PubMed Central PMCID: PMCPMC4063249.

G.D. Bittner, M.S. Denison, C. Z. Yang, M.A.Stoner, G. He. 2014. Chemicals having estrogenic activity can be released from some BPA-free, hard and clear, thermoplastic resins. Environmental Health. 13:103-121. doi: 10.1186/1476-069X-13-41. PubMed PMID: 24886603; PubMed Central PMCID: PMCPMC4063249.

D.C. Riley, G.D. Bittner, M.A. Mikesh, N.L. Cardwell, A.C. Pollins, C.L. Ghergherehchi, S.R. Bhupanapadu Sunkesula, T.N. Ha, B.T.D. Hall, A.D. Poon, M. Pyarali, R.B. Boyer, A.T. Mazal, N. Munoz, R.C. Trevino, T.Schallert, W.P. Thayer. 2015. Polyethylene glycol--fused allografts produce rapid behavioral recovery after ablating sciatic nerve segments. [J Neurosci Res.](http://www.ncbi.nlm.nih.gov/pubmed/25425242) Apr;93(4):572-83. doi: 10.1002/jnr.23514. PubMed PMID: 25425242; PubMed Central PMCID: PMCPMC4329031.

G.D. Bittner, K.K. Rokkappanavar, J.D. Peduzzi. 2015. Application and implications of PEG-fusion as a novel technology to repair injured spinal cords. Neural Regeneration Research. 10:1406-1408.

G.D. Bittner, D.R. Sengelaub, R.C. Trevino, J.D. Peduzzi, M. Mikesh, C.L. Ghergherehchi, T.Schallert, W.P. Thayer. 2016. The curious ability of PEG-fusion technologies to restore lost behaviors after nerve severance. J Neurosci Res. 94: 207-230. online 3 Nov.2015. doi. 1002/jnr 23685

C. L. Ghergherehchi, G. D. Bittner, R. L. Hastings, M. Mikesh, D. C. Riley, R. C. Trevino, T. Schallert, W. P. Thayer, S. Raju Bhupanapadu Sunkesula,, T-A. N. Ha\, N. Munoz, M. Pyarali, A. Bansal, A. D. Poon, A. T. Mazal, T. A. Smith, N. S. Wong, P. J. Dunne. 2016. Effects of extracellular calcium and surgical techniques on restoration of axonal continuity by PEG-fusion following complete cut- or crush-severance of rat sciatic nerves. J Neurosci Res. 94:231-245. Doi. 10.1002/jnr23704.

G.D. Bittner, M. Mikesh, C. L. Ghergherehchi. 2016. PEG-fusion retards Wallerian degeneration and rapidly restores behaviors lost after nerve severance. Neural Regen. Res. 11:217-219. Doi 10.4103/1673-5374.177716.

C.H. McGill, S. R. Bhupanapadu Sunkesula, A.D. Poon,M. Mikesh, G. D. Bittner. 2016. Sealing Frequency of B104 Cells Declines Exponentially with Decreasing Transection Distance from the Axon Hillock. Exp. Neurol. 279:149-158. doi:10.1016/j.expneurol.2016.02.001.

George D. Bittner, Christopher S. Spaeth, Andrew D. Poon, Zachary S. Burgess, Christopher H. McGill. 2016. Repair of traumatic plasmalemmal damage to neurons and other eukaryotic cells. Neu. Regen. Res. 11:1033-1042.  doi: 10.4103/1673-5374.187019.

G.D. Bittner, D.R. Sengelaub, R.C. Trevino, C.L. Ghergherehchi, M. Mikesh. 2017.Robinson and Madison have published no data on whether polyethylene glycol fusion repair prevents reinnervation accuracy in rat peripheral nerve. J Neurosci Res. 95:863-866. doi: 10.1002/jnr.23849.

GD Bittner, DL Sengelaub, CL Ghergherehchi. 2018. Conundrums and confusions regarding how PEG-fusion produces excellent behavioral recovery after peripheral nerve injuries. Neural Regeneration Research. 13: 53-57. doi: 10.4103/1673-5374.224363.

Andrew D. Poon, Sarah H. McGill, Solomon Raju Bhupanapadu Sunkesula, Zachary S. Burgess, Patrick J. Dunne, Edward E. Kang and George D Bittner. 2019.CaMKII and DMSO affect the sealing frequencies of transected hippocampal neurons. J. Neurosci. Res. 96:1208-1222. doi: 10.1002/jnr.24232.

Mikesh M, Ghergherehchi CL, Hastings RL, Ali A, Rahesh S, Jagannath K, Sengelaub DR, Trevino RC, Jackson DM, Bittner GD. 2018. Polyethylene glycol solutions rapidly restore and maintain axonal continuity, neuromuscular structures and behaviors lost after sciatic nerve transections in female rats. J. Neurosci. Res. 96: 1223-1242. doi: 10.1002/jnr.24225.

Mikesh M, Ghergherehchi CL, Rahesh S, Jagannath K, Ali A, Sengelaub DR, Trevino RC, Jackson DM, Tucker HO, Bittner GD. 2018. Polyethylene glycol treated allografts not tissue matched nor immunosuppressed rapidly repair sciatic nerve gaps, maintain neuromuscular functions, and restore voluntary behaviors in female rats. J. Neurosci. Res. 96:1243- 1264. doi: 10.1002/jnr.24227.

Ghergherehchi CL, Mikesh M, Sengelaub DR, Jackson DM, Smith T, Shores JT, Bittner GD. (2019) Polyethylene glycol (PEG) and other bioactive solutions with neurorrhaphy for rapid and dramatic repair of peripheral nerve lesions by PEG-fusion. J Neurosci Methods. 314:1-12. NIHMS1518360, Publ.ID: NSM8215. Doi n1-.1016/jneumeth.2018.12.20.15

Bittner GD, Ghergherehchi CL, Mikesh M. 2019 Surgical Technique and Other Protocols Used Probably Did Not Induce Polyethylene Glycol Fusion of Rat Facial Nerves. JAMA Facial Plast Surg. ;21(1):81. doi:10.1001/jamafacial.2018.1126

Bittner G, Ghergherehchi C, Mikesh M, Sengelaub D, Trevino R, Shores J. S[alomone et al did not induce PEG-fusion repair of severed rat facial nerves.](https://www.ncbi.nlm.nih.gov/pubmed/31400039) Head Neck. 2019 Aug 9. doi: 10.1002/hed.25894. [Epub ahead of print] PMID: 31400039

Vargas SA and Bittner GD. 2019. Natural mechanisms and artificial PEG-induced mechanism that repair traumatic damage to the plasmalemma in eukaryotes. Current Topics in Membranes: Plasma Membrane Repair. 84: 129-167.

Ghergherehchi CL, Sengelaub DR, Mikesh M, Shores JT, Bittner GD. 2019. Alterations in spinal connectivity and remodeling of motoneuron dendritic morphology after sciatic nerve transection with polyethylene glycol axon fusion repair. PLOS One. 14(10): 1-27 e0223443. <https://doi.org/10.1371/journal.pone.0223443>.

Bittner G, Ghergherehchi C, Mikesh M, Senglelaub D, Trevino R, Shores J. 2019. Salomone et al did not induce PEG-fusion repair of severed rat facial nerves. Head Neck. 2019 Oct;41(10):3737-3739. doi: 10.1002/hed.25894. Epub 2019 Aug 9. PMID:31400039.

Smith TA,Ghergherehchi CL, Mikesh M, Shores JT, Tucker HO, Bittner GD. 2020. Polyethylene glycol-fusion repair of sciatic allografts in female rats achieve immunotolerance via attenuated innate and adaptive responses.J Neurosci. Res. 98:2468-2495. PMID: 33008419; PMCID: PMC7532577.

Smith TA GhergherehchiCL, Tucker HO, G. D. Bittner GD.. 2020. Coding transcriptome analyses reveal altered functions underlying immunotolerance of PEG-fused rat sciatic nerve allografts. J. Neuroinflammation. 17:287-311. doi.org/10.1186/s12974-020-01953-8. PMID: 32931034.

Ghergherehchi CL, Shores JT, Alderete J, Weitzel EK, Bittner GD. 2021. Methylene blue enhances PEG-fusion repair of completely severed rat sciatic nerves. Neural Regeneration Research. 16(10):2056-2063. doi.org/10.1186/s12974-020-01953-8. PMID: 33642394; PMCID: PMC8343334.

Kelly C. S. Roballo, Jason P. Gigley, Tyler A. Smith, George D. Bittner, Jared S. Bushman. 2022. Morphological, Functional, and Immunological Peculiarities of Peripheral Nerve Allografts. Nerve Regeneration Research. 17: 721-747. https://doi.org/10.4103/1673-5374.322445

George D. Bittner, Jared S. Bushman, Cameron L. Ghergherehchi, Kelly C.S. Roballo, Jamie T. Shores, Tyler A. Smith. 2022. Typical and Atypical Properties of Peripheral Nerve Allografts Enable Novel Strategies to Repair Segmental Loss Injuries. Journal of Neuroinflammation. 19:60 <https://doi.org/10.1186/s12974-022-02395->

Stephen Lopez MD, George Bittner PhD, Richard Trevino MD. 2023. Rapid and effective fusion-repair of severed digital nerves using neurorrhaphy and bioengineered solutions including polyethylene glycol: A case report. Frontiers in Cellular Neuroscience: In Volume 16 - | <https://doi.org/10.3389/fncel.2022.1087961>

Liwen Zhou, Monzer Alatrach, Ted Zhao, Paul Oliphint, George D. Bittner. 2023 Differential survival of segments of rat sciatic nerves preserved in different storage solutions assessed by novel electrophysiological and morphological criteria. 2023. Neural Regeneration Research. 18:2082-2088. https://doi.org/10.4103/1673-5374.367848

Marshal Mencel and George D. Bittner. 2023. Repair of traumatic lesions to the plasmalemma of neurons and other cells: commonalities, conflicts, and controversies. Frontiers in Cellular Neuroscience. In Press.

Tyler A. Smith, Cameron L. Ghergherehchi, Kevin Zhou, Michelle Mikesh, Cathy Z. Yang, Haley O. Tucker, JuliAnne Allgood, Jared S. Bushman, George D. Bittner.2023.Polyethylene glycol treatment of peripheral nerve allografts in rats requires axon fusion to consistently attenuate innate and adaptive immune responses. Frontiers in Cellular Neuroscience. In Press

Christopher Frost; Abdel Salous, Suvethavarshini Ketheeswaran, Ledibabari M. Ngaage, Phil Hanwright, Cameron Ghergherehchi, Sami Tuffaha, George D. Bittner, Dhananjay Vaidya, Gerald Brandacher, Jaimie Shores. 2023.Polyethylene Glycol Fusion Restores Axonal Continuity and Improves Return of Function in a Rat Median/Ulnar Nerve Denervation Model. Journal of Hand Surgery. In Press

Allgood JA, Bittner GD, Bushman JS. 2023. Repair and Regeneration of Peripheral Nerve Injuries that Ablate Branch Points. Neural Regeneration Research. In Press

1. *PATENTS filed by G.D. Bittner*

*Issued*

*Immediate Axon Fusion with Polyethylene Glycol. EFS ID 9537805, Application number 61446803, Confirmation # 2953, Filed 2/25/2011, Provisional Patent filed on behalf of UTAustin.*

*Repair of Spinal Lesions by PEG-fusion Provisional patent filed 4/29/2022*

In September 2017, Neuraptive executed an exclusive license agreement with the University of Texas at Austin (UT) to a patent application protecting PEG-fusion.

The license agreement between Neuraptive and UT secures exclusive rights to U.S. Patent Application No. 15/597,891, entitled “NERVE TREATMENT METHODS,” by George D. Bittner et al., which is a continuation filing of U.S. Patent Application No.14/001,431 (PCT/US12/26764) and derived from Provisional applications No. 61/446,803 and No. 61/578,930. The priority date for this case is February 25, 2011.

The continuation was filed to create a claim set that more comprehensively protects the PEG-fusion technology. Neuraptive directed the drafting of the claims in this continuation with the assistance of counsel, Dave Parker of Parker Highlander (Austin).

The US Patent and Trademark Office has issued a Notice of Allowance for the ‘891 case for claims protecting the method of inducing axonal fusion within a severed nerve using the sequential administration of pharmaceutical agents including the membrane fusogen PEG and the antioxidant methylene blue. The specification is well detailed and reduction to practice of the method is thorough. Dependent claims are directed at more specific embodiments.

Abstract: The present disclosure is directed to the use of fusogenic compounds such as polyethylene glycol (PEG) in combination with antioxidants, calcium-containing and calcium-free solutions for treating damaged nerves, such as for reconnecting severed nerves.

 **An additional Provisional patent is in process of being filed by UTA.**

Storage solutions for organs, tissues, and VCAs to maintain axonal viability

*Issued*

Materials and food additives free of endocrine disruptive chemicals and method for detecting endocrine disruptive activity. Filed 5/10/02. US Patent #6,894,093 Issued May 17, 2005.

**Additional Service and Research**

In my off-campus research begun in 2000, I developed sensitive *in vitro* robotic assays to detect xenobiotic chemicals having mammalian hormonal activity (i.e. endocrine disruptors). I used such data to develop polymer formulations and bio-engineer protocols to produce plastic and silicone products that do not release chemicals having hormonal activity (especially estrogenic or androgenic activity). In the last decade, this basic and applied research has been funded by more than 15 NIH and NSF grants totaling over $8M (over $12M from all sources). **The University of Texas at Austin was also recognized on all papers published describing these data.** I believe that my scientific colleagues and I were the leading researchers in this field, i.e., an intersection of cellular/molecular endocrinology and polymer chemistry that has obvious implications for human health and environmental contamination. This off-campus research still has much potential to help solve a major health problem that until recently has gone largely unrecognized—the release of xenobiotic chemicals having hormonal activity by plastics and other substances. Our conclusions are strongly supported by scientists and administrators at NIH and NSF—and strongly

 This off-campus research was performed by CertiChem (aka CCi) and PlastiPure (aka PPi). The mission of CertiChem was to develop sensitive, accurate, high throughput assays to detect hormonal activity. CertiChem is primarily an R&D entity. The mission of PlastiPure was to develop polymer formulations, resins and manufacturing procedures/protocols for plastic and silicone-based products that do not release chemicals having hormonal activity. Our data showed that almost all existing plastics and silicone products release chemicals having easily detectable estrogenic activity. PlastiPure completed the transition from an R&D entity in 2008 to a viable commercial entity in 2011. We closed PPi as a commercial entity in the summer of 2020.

 As consulting CEO for CertiChem and consulting Chief Scientific Officer for PlastPure, my main task was to direct scientific research and development of patentable chemicals, formulations and/or products, and direct and write SBIR grant proposals in collaboration with PIs employed by the firm. We are selling and closing CCi by January 2021. An NSF or NIH SBIR PI (or co-PI) must be employed at least 51% time by CertiChem or PlastiPure (My total time combined for both firms was less than 18%). In this capacity, I was largely responsible for writing peer-reviewed research papers, deciding the Specific Aims and directing the writing of the following grants awarded since 2001:

 **For CertiChem:**

NIH/NIEHS R44 ES026470 01-01 (PI= CZ Yang) ~12/1/2015 - 5/30/2018

 Validation of an In Vitro Assay for Androgenic Activity

 Total award $1,213,515

NIH/NIEHS R43 ES025075-01 (PI = CZ Yang) 09//01/2014 – 2/28/2015

 Safer Personal Care Products

 Total Award $141,079

NSF 0912601-03 (PI = CZ Yang) 09/15/2010 – 8/31/2014

Food antioxidants With or Without Estrogenic Activity

Total award: $500,000

Supplement about $400,000 (final amount pending)

NSF 0912601-01 (PI = CZ Yang) 07/01/2009 – 12/31/2009

Food antioxidants With or Without Estrogenic Activity

Total award: $99,898

NIH/NIEHS 5R44ES014806-03 (PI = CZ Yang) 9/01/2008 – 8/31/2009

In Vitro Robotic Assay for Anti-Estrogenic Activity

Total award: $446,359

NIH/NIEHS 2R44ES014806-02 (PI = Yang) 9/11/2007 – 8/31/2008

In Vitro Robotic Assay for Anti-Estrogenic Activity

Total Award: $476,510

NIH/NIEHS 1 R43 ES011806-01 PI = C.Z. Yang) 06/01/2006 – 12/31/2006

In vitro Robotic Assay for Anti-Estrogenic Activity

Direct Cost: $72,788, total Cost = $121,756

NIH/NIEHS 1 R44 ES011469-02 PI = C..Z. Yang 04/01/2004 – 04/30/2007

In vitro Robotic Assay for Estrogenic Activity

Direct Cost: $901,209, Total Cost: $1,350,618

1 R43 ES011469-01 PI = C.Z. Yang (PI) 04/01/2001 – 10/01/2001

In vitro Robotic Assay for Estrogenic Activity

Direct Cost: $75,000

**For PlastiPure**

NIEHS 1 R43 ES018083-02 PI = D.Kline 08/20/2013 – 8/19/2015

A Hard and Clear, Estrogen-Free Replacement for Bisphenol-A Based Polycarbonates

Total Cost: $956,000

 NSF IIP-1127553 PI = D Kline 09/15/2011-08/31/2014

 Flexible Plastic Packaging Without Estrogenic Activity (EA)

 Total cost: $488,236

 Supplement$100,000

NIEHS 1R44ES019442-02,03 PI = S. Yaniger 01/01/2011 – 2/28//2013

Baby bottles that release no chemicals having estrogenic activity

Total Cost: $1,285,871

NIEHS 1R44ES019442-01 PI = S. Yaniger 09/01/2010 – 12/31/2010

Baby bottles that release no chemicals having estrogenic activity

Total Cost: $141,830

NSF IIP-1013865 PI = D. Klein 07/01/2010 - 12/31/2010

Flexible Plastic Packaging Without Estrogenic Activity (EA)

Total Cost: $150,000

NIEHS 1 R43 ES018083-01 PI = S.Yaniger 06/01/2010 – 11/30/2010

A Hard and Clear, Estrogen-Free Replacement for Bisphenol-A Based Polycarbonates

Total Cost: $222,248

NIEHS 2R44ES016964-02 PI= S. Yaniger / D. Klein 08/14/2009 – 07/31/2010

Estrogen free Polymer Formulations for Food Packaging and Baby Products

Total Cost: $1,207,230

NIEHS 1R43ES016964-01 PI = J Laiz 06/01/2008 – 11/30/2008

Estrogen Free Polymer Formulations for Food Packaging and Baby Products

Total Cost: $134,264

CCi was selected by ICCVAM/NICEATM to perform a single-lab validation study using MDA-Kb2 cells to detect androgenic activity (AnA in robotic and manual formats. Items **C1 and C2** below lists some of our basic (**C1**) and applied (**C2**) peer-reviewed publications. My role in both firms was to guide their scientific direction and take the lead in writing grant proposals and peer-reviewed papers.

At CCi, we  developed, robotized, and validated with ICCVAM/NICEATM/OECD  a battery of *in vitro* assays using MCF-7 cells or BG1-Luc cells to detect EA\*\* and MDA-Kb2-cells to detect AnA\*\* that are the most accurate and sensitive currently available, in part due to our developing Confirmation Assays. Using these assays, we have demonstrated that the great majority of plastic, silicone and personal care products (PCPs) release a variety of chemicals having EA\*\*/AnA\*\*. Using these assays, we have created a knowledge base of commonly-used chemicals and materials that are EA\*\*/AnA\*\* or EA/AnA\*\*-free and can be used to make plastics and PCPs. Using this knowledge base and a knowledge of polymer and other chemistry, we have identified or developed formulations for products that leach ***no*** chemicals having detectable EA\*\*/AnA\*\* after extraction with hydrophilic or hydrophobic solvents or after common-use stresses of heating, boiling microwaving, UV radiation. This approach differs from that currently used by various commercial, academic, regulatory or government entities that address problematic ingredients having EA\*\*/AnA\*\* (e.g., BPA) one-at-a time without considering that many other ingredients also have significant hormonal activity -- and that more than one solvent is needed for appropriate extraction and that products need be exposed to common use stresses that can create new chemicals. Furthermore, replacing chemicals one-by-one is much more costly than reformulating to eliminate all ingredients having EA\*\*/AnA\*\*.

At CCi, my fellow scientists and I believe that when a large variety of EA\*\*/AnA\*\*-free\*\* products become available to the public, this will reduce the potential health problems associated with EDCs of which the most frequent types of hormonal activity in the “chemical commons” are from leached chemicals having EA\*\*/AnA\*\*. I believe that CCi is ***the*** leading laboratory in the intersection of hazard analysis, public awareness and genuine health-related product solutions to a problem now being recognized by government agencies and consumer groups.

**C1. Representative peer-reviewed papers on assays to detect EDCs with EA**

C.Z. Yang, W. Casey, M. Stoner, G.J .Kollessery, A.W. Wong and G.D. Bittner. 2014. A robotic MCF-7:WS8 cell proliferation assay to detect agonist and antagonist estrogenic activity. Toxological Sci. 137:335-349.

M.A.Stoner, C.Z.Yang, and G.D.Bittner. 2014. A Robotic BG1Luc Reporter Assay to Detect Estrogen Receptor Agonists. Toxicology in Vitro. 28: 916–925.

These two papers describe our robotic assays for EA that have very high concordance with ICCVAM/ECCVAM meta-analyses for test chemicals. Specifically, our robotic BG1Luc assay has high (100%) concordance for the presence or absence of detectable EA with ICCVAM meta-analyses for 27 test chemicals. When chemicals tested in common by both assays are compared, this robotic BG1Luc assay has 100% concordance with the ICCVAM manual BG1 assay for 27 test chemicals, 100% concordance with CERI for 20 test chemicals, and 100% concordance with a robotic MCF-7 assay for 27 test chemicals. In contrast, the yeast estrogen screening (YES) assay has only 47% (7/15) concordance with any of these other assays for 15 test chemicals. When sensitivities of these different assays are compared to detect the EA of the same test chemical as defined by its EC50, our robotic BG1Luc assay is more sensitive for 15/20 and one tie out of 21 chemicals reported by ICCVAM meta-analyses , i.e., is more sensitive (p < 0.001, Chi Squared test) for 15 chemicals whose EC50s can be directly compared.  Compared to ICCVAM BG1 manual data for 22 chemicals, our robotic BG1Luc assay is more sensitive for 14/22 (p < 0.0.001).  Compared to CERI manual assays, the robotic BG1 is more sensitive for 18/20 test chemicals (p <0.0001). Compared to the YES assay, the robotic BG1 assay is more sensitive (p < 0.0001) for 15/15 chemicals whose EC50s can be directly compared. In contrast, with respect to the robotic MCF-7 assay as reported for ICCVAM validation results, the BG1Luc is more sensitive for only 4/27 chemicals whose EC50 can be directly compared, i.e. the MCF-7 assay is more sensitive (and has as high a concordance) with a high significance (p < 0.0001) compared to our EC50 from our robotic BG1Luc, ICCVAM manual BG1Luc, CERI, and YES assays and ICCVAM EC50 meta-analyses.

 **C2.** **Representative peer-reviewed papers on release of EDCs having EA from various consumer products.**

C. Z. Yang, S. I. Yaniger, V. C. Jordan, D. Klein and G.D. Bittner. 2011. Most Plastic Products Release Estrogenic Chemicals: A Potential Health Problem That Can Be Solved. Environmental Health Perspectives. 119: 989-996.

S.L. Myers, C.Z.Yang, G.D. Bittner, K.L. Witt, R.R. Tice, D.D. Baird. 2014. Estrogenic and Anti-Estrogenic Activity of Off –The-Shelf Hair and Skin Products. Journal of Exposure Science and Environmental Epidemiology. 25:271-277.

G.D.Bittner, M. A. Stoner, C. Z. Yang. 2014. Estrogenic chemicals often leach from BPA-free plastic products that are replacements for BPA-containing polycarbonate products. Environmental Health 13:41-54.

G.D. Bittner, M.S. Denison, C. Z. Yang.  2014. Chemicals having estrogenic activity can be released from some BPA-free, hard and clear, thermoplastic resins. Environmental Health. 13:103-121.

These papers report that consumer products in two general categories--—plastics and personal care products (PCPs) – release chemicals thast have easily-detectable EA as measured by our two robotic assays for EA. The data for PCPs are described in the body of this proposal. The results of our two hazard studies of BPA-replacement resins (aka polycarbonate or PC resins) and PC-replacement products. Like PC resins, these PC-replacement resins are “hard, clear, and reusable”. Some (4/14) of these unstressed and stressed BPA-free resins leached chemicals having significant levels of EA, including one polystyrene, and three Tritan™ resins, the latter reportedly EA-free. Exposure to UV radiation in natural sunlight resulted in an increased release of EA from Tritan™ resins. Ten unstressed or stressed glycol-modified polyethylene terephthalate (PETG), cyclic olefin polymer (COP) or copolymer (COC) thermoplastic resins did not release chemicals with detectable EA under any test condition. Similarly, many unstressed and stressed, PC-replacement-products made from acrylic, polystyrene, polyethersulfone, and Tritan™ resins leached chemicals with EA, including products made for use by babies. Exposure to various forms of UV radiation often increased the leaching of chemicals with EA. In contrast, some BPA-free PC-replacement products made from glycol-modified polyethylene terephthalate or cyclic olefin polymer or co-polymer resins did not release chemicals with detectable EA under any conditions tested.

These two hazard assessment surveys showed that many BPA-free PC- replacement resins and products still leached chemicals having significant levels of EA, as did their BPA-containing PC counterparts they were meant to replace. That is, BPA-free did not mean EA-free. However, this study also showed that some PC-replacement resins and products did ***not l***each chemicals having significant levels of EA. That is, EA-free PC-replacement resins and products can be made in commercial quantities at prices that compete with PC-replacement products that are not BPA-free. Since plastic products often have advantages (price, weight, shatter-resistance, etc.) compared to other materials such as steel or glass, our data show that is not necessary to forgo those advantages of plastics in order to avoid release into foodstuffs or the environment of chemicals having EA that may have potential adverse effects on our health or the health of future generations.

**Detailed Research Support. G. Bittner = sole P.I. unless otherwise noted; direct and indirect and total costs**

**Previous Research Support for last 5 years**

**1) Title:** Enhanced Regeneration and Repair of Severed Spinal and PNS Axons

 **Time Commitment:** 1% [0.12 person-months]

 **Agency:** Lone Star Paralysis Foundation

 **Grants Officer:** Doug English, 7900 FM 1826, Bldg. II Rm. 105, Austin, TX 78737

 **Performance Period and Funding: Gifts. All direct costs. No overhead costs.**

1/16-12/16 $60,000 +10,000 eqpt

1/16- 7/16 $20,000 Dr. Richard Trevino (PI) at WellSpan York Hospital and G Bittner (Basic science advisor) to U Pennsylvania Pharmaceutical lab for FDA IND of sterile PEG solution for York IRB

1/17-12/17 $60,000

 1/18- 8/30/18 30K (3/7 )+35K(5/22) +10K(8/6) +90K 8/30) = $165,000

1/17-12/17 $60,000

 1/18- 8/30/19 30K (3/7/18 )+35K(5/22/18) +10K(8/6/18) +90K 8/30/18) = $165,000

 9/2019-5/2020 $60,000

 5/2020 – 3/2021 $50,000

3/2021 - 1/2024 $195,000 direct costs to support postdoctoral fellows on spinal research

 **Description/Aims:** The goal is to modify our PEG-fusion technology to repair spinal cord and PNS injuries. As a gift, all funds are direct costs only with no overhead costs to support pilot studies in basic research with no specific Aims

 **No specific scientific or budgetary overlap**

**2) Title**: R01NS081063 A novel bioengineered technique to rapidly and permanently repair cut PNS nerves

 **Time Commitment:** 10% [1.20 person-months]

 **Agency:** NIH-NINDS

 **Grants Officer:** Lyn B. Jakeman, NIH, 9000 Rockville Pike, Bethesda, Maryland 20892

 **Performance Period and Funding Level:**

 9/15/12—6/30/18 $1,860,200 Total direct + indirect costs originally awarded... Total award after across the board cut of 17.5% for all NIH R-01 non-modular grants.

 **Description/Aims:** Use cultured B104 cells and *ex vivo* methods to develop the best sequence of solutions for PEG-fusion mostly in acutely cut rat sciatic nerves as examined *in vivo* by several behavioral and morphemetric assay methods

**Aim 1.** **Determine what bio-engineered solutions or conditions best increase or decrease sealing *in vitro* and PEG-fuse-repair acutely severed (cut) rat sciatic nerves *ex vivo* and then *in vivo****.*  We have published six papers on how various substances (including PEG and MB), biochemical pathways, and transection sites increase or decrease the ability of an axolemma to seal after transection. We have used these data to develop improved PEG-fusion protocols to repair acutely cut sciatic nerves as described in eight papers whose major findings include the role of Ca2+, nerve stretch, length of damaged membrane, MB, PEG concentration and application time on SFI recovery, prevention of Wallerian degeneration and plasticity responsible for behavioral recoveries.

 **Aim 2**. **Determine what bioengineered solutions best increase survival of rat sciatic axons chronically severed for up to 10 days *in vivo*.**

 We obtained pilot data that Ca2+-free PlasmalyteTM solutions at 20° C can increase survival of severed rat sciatic axons for at least three days. For this Aim, we used allograft model systems.

 **Aim 3**. **Determine what treatment solutions and temperatures best PEG-fuse-repair acute interposition autografts of rat sciatic axons *ex vivo* and *in vivo*.** Pilot studies only.

 **Aim 4.** Determine what treatments best PEG-fuse-repair acute allografts of rat sciatic axons *ex vivo* and *in vivo*. Since discovering the unexpected PEG-fusion success of allografts in the third year (2015) of this R-01, we have examined rapid and dramatic behavioral recovery, lack of rejection of allografts even between Sprague-Dawley and Long-Evans strains, ability to store allografts in PlasmalyteTM for at least 3 days, dramatic prevention of Wallerian degeneration, and insights into mechanisms underlying neuronal plasticity.

7/15/15 - 6/30/18. $153,000 supplement total direct + indirect costs.

 Supplement to support a graduate student to begin to investigate innate and adaptive immunological responses to begin to explain why PEG-fused donor allografts of rat sciatic nerves are not rejected even though they are allogenic, in an unprotected environment, not tissue matched and not immune suppressed. If not PEG-fused, such allografts are rapidly rejected within days.

 **No scientific or budgetary overlap**

**3) Title:** Neuraptive,Inc. Sponsored Research Agreements (SRAs)

 **Time Commitment:** 1% [0.12 person-months]

 **Agency:** Neuraptive Therapeutics

 **Grants Officer:** David Jackson, Lafayette, CO 80026

 **Performance Period** **and Funding Level:**

Neuraptive Sponsored Research Agreement (SRA). Direct plus indirect costs.

 5/1/2017- 1/1/2018. $56,299

Pilot study of glucocorticoids (GCs) in rat sciatic nerve PEG-fusion model $25,000

Pilot Study of Neuraptive Device Effectiveness in Rat and Rabbit Sciatic Nerve PEG-Fusion Model $31,299

 **Description and Aims:**

|  |  |  |
| --- | --- | --- |
| P1 | **Pilot study of glucocorticoids (GCs) in rat sciatic nerve PEG-fusion model** Pilot study to examine effects of methyl prednisolone, progesterone, dexamethasone, and TrA on the inflammatory response of PEG- fused sciatic axons at 7, 14, or 21 post-operative days.  | Assess effects morphologically and functionally |
| P2 | Pilot study to examine formulations of GCs for topical nerve administration in rat sciatic nerve PEG-fusion model | Assess effects morphologically and functionally |
| P3 | Pilot structure-activity study of formulated GCs in rat sciatic nerve PEG-fusion model | Assess effects morphologically and functionally |

***Pilot Study of Neuraptive Device Effectiveness in Rat and Rabbit Sciatic Nerve PEG-Fusion Model $31,300***

Pilot study of Neuraptive Device Effectiveness of Sciatic Nerve PEG-Fusion in rat and rabbit sciatic nerve PEG fusion, and assess the effect morphologically and functionally. Examine the effects of the Neuraptive Device on CAP fusion and SFI-scored behavior of PEG- fused sciatic axons acutely and/or at 7, 14, 21, 28, 35 and 42 post-operative days. Examine the effects using 5 acute rat experiments, 1 acute rabbit experiment, and 10 chronic rat experiments with parameters as specified by Neuraptive.

 Gifts in addition to Neuraptive SRAs: (direct costs, no overhead costs)

Neuraptive Research Gift for Equipment 5/5017 $15,000

Neuraptive Research Gift for PEG-fusion Research 10/2017 $50,000

Neuraptive Research Gift for PEG-fusion Research 5/2018 $20,000

**2. Title: W81XWH-19-2-0054. Log # OR180077.** Immediate repair with accelerated recovery from peripheral nerve injury using PEG-fusion technologies

 **Time Commitment:** 10% [1.2 person-months]

 **Agency:** DOD PRORP grant

 **Grants Officer:** Miriam Redington, Science Officer;301.619.3477 Miriam.E.Redington.CIV@mail.mil

 **Performance Period and Funding:** 9/15/2019 – 9/14/2022. $ 824,911 total costs. G Bittner submitting and corresponding PI. $510,046 total costs to UTA, $188,988 to Johns Hopkins Medical School (Jaimie Shores PI), and $114,877 To DOD METIS (Erik Weitzel, PI, Joseph Alderete Key Collaborator). *Pending. Transfer of additional $25,000 from METIS to UTA.*

 **Description/Aims:** Pilot study to determine the possible efficacy of PEG-fusion technology on single transection peripheral nerve injuries (PNIs) repaired by primary PEG-fusion and segmental loss (ablation type) PNIs repaired by PEG-fused allografts in rats and swine.

 **Aims** (9/1/2021 revision)

**Specific Aims:**

**Aim 1. Extend the time for successful PEG-fusion repair of single transection PNIs segmental ablation-type PNIs with allografts in a rat sciatic nerve model**.

**Aim 1A1.** **Determine effects of 0.5% and 1% MB.**

**Aim 1A2. Train new lab manager, Dr Cathy Yang (hired 6/2/2020) in behavioral testing, TEM, IHC, and microsurgery required for PEG-fusion of singly cut and ablated segment sciatic nerves, the latter called PEG-fused PNAs**.

**Aim 1A3. Determine the maximum time after a PNI for successful PEG-fusion repair**.

**Aim 1B. Short term (1-2 min) exposure to high concentrations (50%w/w) of 3.235 kD PEG by itself reduces inflammatory responses in ablation type PNIs in wildtype SD/SD rat host and donor allograft repair.**

**Aim 1C. Allografts can be stored at least 72h in Plasmalyte at 4oC and successfully used for PEG-fusion repair of ablation-type PNIs.**

# Aim 2 at JHU and SA (RESTOR,METIS)

**Aim 2A-C. Determine if PEG-fusion repairs of single transection and ablation-type PNIs using a large animal model (swine median nerve) having nerve diameters and immune responses more like humans are comparable to results of Aims 1A-C using a small animal model (rat sciatic). In Aim 2, all surgeries will be done at Johns Hopkins or RESTOR and tissues sent to UTA for processing.**

**Aim 2A. Single transection or ablation type PNIs in swine median nerves can be successfully repaired by PEG-fusion at least 24h p.i. without any intervention.**

**Aim 2B. Single transection or ablation type PNIs in swine median nerves can be successfully repaired by PEG-fusion at least 36h p.i. and reduce inflammation if MP is directly applied to the lesioned area immediately after PEG-fusion repair.**

**Aim 2C. Allografts of swine median nerves can be stored at least 72h in Plasmalyte at 4oC and successfully used for PEG-fusion repair of ablation-type PNIs at 24 or 36h p.i.**

**CURRENT SUPPORT**

**1) Title:** Enhanced Regeneration and Repair of Severed Spinal Axons

 **Time Commitment:** 1% [0.12 person-months]

 **Agency:** Lone Star Paralysis Foundation

 **Grants Officer:** Doug English, 7900 FM 1826, Bldg. II Rm. 105, Austin, TX 78737

 **Performance Period and Funding: (Gift: all direct costs)** 3/2021 - 1/2024

$195,000 direct costs to support postdoctoral fellows on spinal research

 **Description/Aims:** The goal is to modify our PEG-fusion technology to repair spinal cord and PNS injuries. As a gift, all funds are direct costs only with no overhead costs to support pilot studies in basic research with no specific Aims

**3) Title: W81XWH2020029. Multimodal approach to improve functional recovery following acute and delayed nerve repair [****for single transections repaired by PEG-fused neurorrhaphy and segmental loss ablations repaired by PEG-fused *auto*grafts]**

**Role:** PI: UT-Austin site on subcontract to SA (Joe Alderete, PI)

 **Time Commitment:** 10% [1.20 person-months]

 **Agency:** DOD AFIRM III grant

 **Grants Officer:**

 **Performance Period and Funding:** 12/1/2021 - 09/30/2023; $264,534 direct costs, $419,286 total costs for UTA Subcontract Site Project Total. Subcontract for AFIRM III grant funded for about $1,800,000 to Joseph Alderete, PI. There is a separate AFIRM III grant also funded with Jamie Shores (JHU) for about $6,000,000 for clinical trials of single transections repaired by PEG-fused neurorrhaphy and segmental loss ablations repaired by PEG-fused *auto*grafts for which I am a scientific advisor.

**Description.** UTA subcontract to train SA surgeons in PEG-fusion and to examine some specific aspects of PEG-fusion in singly transected PNIs repaired by neurorrhaphy and segmental loss PNAs repaired by isograft PNAs.

**Specific Aims**:

**Aim 1:** Obtain multimodal PEG- fusion baseline data and Environmental Augmentation data on female *Sprague Dawley* rat sciatic, single cut, nerve model systems for behavioral recovery (SFI, von Frey tests), axonal/NMJ/muscle morphology and function (CAPs, CMAPs). Months 0-12

**Aim 1A:** Train four surgeons from DOD RESTOR San Antonio to PEG-fuse singly cut rat sciatic nerves.\ assayed by weekly SFI behavioral tests for 6 weeks. 6 rats/surgeon. 24 Sprague Dawley (SD) chronic rats. Months 0-6.

**Aim 1B:** Baseline Data . PEG-fuse *singly cut* Sprague Dawley rat sciatic nerves enhanced by FK506 application assayed by behavioral recovery (SFI, von Frey tests), axonal/NMJ/muscle morphology and function (CAPs, CMAPs). Compare to PEG and NC historical data. 15 Sprague Dawley (SD) chronic rats. Months 4-12

**Aim 2:** Baseline data and Environmental Augmentation data. Obtain multimodal PEG- fusion baseline data on female *Lewis* rat sciatic, autograft, nerve model systems for behavioral recovery (SFI, von Frey tests), axonal/NMJ/muscle morphology and function (CAPs, CMAPs). Months 0-24

**Aim 2A.** Baseline Data. PEG-fuse and Negative Control (NC) *auto*grafts of 0.5cm length sampled 3 each at 7,21,42d PO for axonal/NMJ/muscle morphology and function (CAPs, CMAPs) and at least 6 each weekly for 42d for behavioral function (SFI, von Frey tests). 15 rats for each PEG and NC protocol. 30 chronic Lewis rats, 15 acute donor Lewis rats

**Aim 2B.** Baseline Data. PEG-fuse and Negative Control (NC) autografts of 1.0 cm length sampled 3 each at 7,21,42d PO for axonal/NMJ/muscle morphology and function (CAPs, CMAPs) and at least 6 each weekly for 42d for behavioral function (SFI, von Frey tests). 15 rats for each PEG and NC protocol. 30 chronic Lewis rats, 15 acute donor Lewis rats Months 8-22

**Aim 2C:** Environmental Augmentation data. PEG-fuse and Negative Control (NC) autografts of 1.0 cm length sampled 3 each at 21,42d PO for axonal/NMJ/muscle morphology and function (CAPs, CMAPs) and at least 6 each weekly for 42d for behavioral function (SFI, von Frey tests). 12 rats for this PEG protocol. 12 chronic Lewis rats, 6 acute donor Lewis rats Months 12-22

**Title:** **R-01 Proposal.** **Translating Novel Peripheral Nerve Allograft Technologies Toward Clinical Use**

$3,819,218. George Bittner submitting and overall PI George Bittner, Jared Bushman Subcontract PI at U. Wyoming (Larimie) and Jaimie Shores (PI Johns Hopkins University)

 **Time Commitment:** 10% [1.2 person-months]

 **Agency:** NIH

 **Grants Officer:** TBD

 **Performance Period and Funding:** 4/1/2023- 3/31/2028 $3,819,218. total. Austin total direct and indirect costs. About $2,000,000

**Aim 1. Develop and merge axon fusion and localized ISN**. Confirm strong preliminary data that show proof of principle for axon fusion and localized ISN separately and together are complementary. Determine the fate of donor cells within the PNAs and their contribution to long-term nerve function.

**Aim 2: Extend the post-injury (PI) time for successful PEG-fusion of a PNA.** Confirm preliminary data that PEG-fusion can be achieved at least 36 h post injury (PI). Confirm that storage solutions and conditions can be developed to slow Wallerian degeneration. Collaborate with a licensed human donor tissue procurement organization to translate the findings in rats to human nerve segments recovered under realistic conditions.

**Aim 3: Confirm that axon fusion and localized ISN separately and together can also be obtained in a larger animal (swine).** Extend preliminary findings of successful axon fusion in swine and combine with method of localized ISN in both short (3 cm) and long (8 cm) ablation defects.

**DOD RTRP Title: A multi-modal/multi-institutional approach to reduce VCA immunogenicity and improve function**

**Multiple PIs**: George D Bittner, PhD submitting PI Jamie Shores MD, Joseph Alderete, MD

**Focus Area:** Reduce the risks of VCA-associated immunosuppression.

1,500,000 direct plus indirect. $420,000 direct + Indirect for UTA

*Specific Aim 1* will examine PEG-fusion repair of nerves in VCAs

Specific aim 2 will examine localized immune suppression.

*Specific aim 3* will test the combined treatment of axon PEG-fusion of VCAs and localized immune suppression

**Title: Novel PEG-fusion therapy for acute and chronic spinal cord injury**

\***Major Goals: Determine success pf PEG-fusion for 0-14d after acute spinal cord injury using bridge and spanning methods of repair**

Project Number: 26-7724-56

Name of PD/PI: George D Bittner

\*Source of Support: Neuraptive Therapeutics, Inc, POC matching funds

\*Primary Place of Performance: University of Texas at Austin

Project/Proposal Start and End Date: (MM/YYYY) (if available): 1/1/2023-12/31/2023

\* Total Award Amount (including Indirect Costs): $125,000

**Title: Novel PEG-fusion therapy for acute and chronic spinal cord injury**

\*Major Goals: **Determine success pf PEG-fusion for 0-14d after acute spinal cord injury using bridge and spanning methods of repair**

Project Number: 19-1774-13

Name of PD/PI: George D Bittner

\*Source of Support: University of Texas at Austin, POC grant

\*Primary Place of Performance: University of Texas at Austin

Project/Proposal Start and End Date: (MM/YYYY) (if available): 1/1/2023-12/31/2023

\* Total Award Amount (including Indirect Costs): $125,000

 **OTHER SCIENTIFIC POSITIONS held by PI: Adjunct Professor, Department of Physiology, UTMB Medical School (no salary or other compensation)**

 **SUPPORT of Undergraduate students, Graduate Students, Postdoctoral fellows**

 In the last year, 5 undergraduates received from UT received $1,000 research fellowship funds (Carrera, Arya, Zhao, Alatrach, Marcel) for supplies & animals and two received summer fellowships of $2500 (Arya), $4000 (Montoya), or 6,000 (Vargas) or about $17,500 total. Undergraduates also volunteer time to be trained in animal testing or other techniques (about $10,000/yr total).About $37,500 total non-grant support. Once trained they are then paid by grant funds (about $20,000/yr total). About $3,000 by non DOD grants (Lone Star Paralysis Foundation)..

 In the last year, four graduate students have been paid by one semester fellowships (about $12,000 each semester in tuition, fringe and tuition direct costs) by UTA or non-DOD sources (Lone Star Paralysis funds (Smith: two semesters, Ghergherehchi: two semesters; Zhou (two semesters), Mencel (one semester). About $72,000 total

 In the last year, one postdoctoral fellow (Ghergherehchi) was provided postdoctoral fellowship funds ($4,000) for one month by LSPF.

 *PATENTS filed by G.D. Bittner*

*Immediate Axon Fusion with Polyethylene Glycol. EFS ID 9537805, Application number 61446803, Confirmation # 2953, Filed 2/25/2011, Provisional Patent filed on behalf of UTAustin.*

In September 2017, Neuraptive executed an exclusive license agreement with the University of Texas at Austin (UT) to a patent application protecting PEG-fusion.

The license agreement between Neuraptive and UT secures exclusive rights to U.S. Patent Application No. 15/597,891, entitled “NERVE TREATMENT METHODS,” by George D. Bittner et al., which is a continuation filing of U.S. Patent Application No.14/001,431 (PCT/US12/26764) and derived from Provisional applications No. 61/446,803 and No. 61/578,930. The priority date for this case is February 25, 2011.

The continuation was filed to create a claim set that more comprehensively protects the PEG-fusion technology. Neuraptive directed the drafting of the claims in this continuation with the assistance of counsel, Dave Parker of Parker Highlander (Austin).

The US Patent and Trademark Office has issued a Notice of Allowance for the ‘891 case for claims protecting the method of inducing axonal fusion within a severed nerve using the sequential administration of pharmaceutical agents including the membrane fusogen PEG and the antioxidant methylene blue. The specification is well detailed and reduction to practice of the method is thorough. Dependent claims are directed at more specific embodiments. The present disclosure is directed to the use of fusogenic compounds such as polyethylene glycol (PEG) in combination with antioxidants, calcium-containing and calcium-free solutions for treating damaged nerves, such as for reconnecting severed nerves.

Neuraptive is in the process of being acquired by Axogen for about 44 million. 18M cash, 6 M upon FDA final approval of PEG-fusion pocess and 20M upon completion of Neuraptive clinical trial. DOD has also funded a clinical trial to be conducted by 6m in AFIRM III funds, PI Jaimie Shores, Johns Hopkins University based in part on results from AFIRM III funds in a separate 1.8M grant to Joseph Alderete PI, METIS ($420,000 subcontract to UTA). This sale should provide UTA with $500,000-$1,000,000 in patent licensing fees plus additional monies from ongoing sales. Dr. Bittner and Lonestar Paralysis Foundation will receive some of these and other monies from this sale and future activities. Much of these monies will go to support PEG-fusion research in Dr. Bittner’s Laboratory.

 **Two additional Provisional patents filed by UTA.**

Process for repair of ablation type peripheral nerve injuries by PEG-fused allografts that require no tissue matching or immune suppression.

Process for repair of spinal cord injuries by PEG-fused allografts that require no tissue matching or immune suppression.

10/21/2021

George D. Bittner, AAAS Fellow
Professor of Neuroscience

Patterson Laboratories, Room 321
University of Texas
Austin, TX 78712
512-471-5454 (O)
512-923-3735 (C)
512-471-9651 (F)
[bittner@mail.utexas.edu](file:///C%3A%5CUsers%5Cgbittner%5CDesktop%5CPC.MAC%20DOCS%20%207.28.10%5Cforms%5Cbittner%40mail.utexas.edu)